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ABSTRACT 
Objective: To systematically review the methodological quality of, and 
evaluate the evidence from trials assessing the efficacy of exercise 
interventions for improving sleep, fatigue and mood after breast cancer 
treatment.   Methods: The search strategy reviewed the English language 
literature of randomised controlled trials (RCTs) from four databases (Ovid 
MEDLINE, Embase, Cochrane Central Register of Controlled Trials and 
EBSCO) and hand searched key journals.  Seven studies met criteria for 
inclusion the review.  Effects sizes were calculated and methodological 
quality assessed using the Clinical Trials Assessment Measure.  Results: 
One study was rated as high methodological quality.  The results suggest 
that a combined intervention approach incorporating physical exercise and 
cognitive behavioural strategies may be more effective for improving 
psychosocial outcomes, than stand alone approaches.  However, the lack of 
studies assessing sleep made it difficult to summarise the evidence.  Failure 
to blind the outcome assessor and intervention contamination were the most 
prevalent methodological shortcomings.  Adverse events were assessed and 
reported in two studies.  Conclusions: The trials reviewed suggest that 
exercise may help to improve sleep, fatigue and mood following breast 
cancer treatment.  However, the beneficial effects of exercise may vary as a 
function of patient-specific and disease-specific factors, as well intervention 
type.  Future RCTs should use appropriate comparisons of the different 
intervention elements and pay greater attention to sleep problems following 
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breast cancer treatment, as this is a much neglected area in this patient 
group. 
 
Keywords: breast cancer; exercise interventions; sleep; fatigue; anxiety; 
depression. 
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INTRODUCTION 
 
1.1  Description of underlying health problem 
 
Breast cancer affects 41,700 people in the UK each year.  There are 12,700 
deaths from the disease annually and one in nine women will develop breast 
cancer.  Breast cancer incidence is increasing but improved treatment 
means that survival is also increasing (Meuser et al. 2001).  Women who 
survive breast cancer experience a wide range of disease and treatment-
related problems, including sleep difficulties, fatigue, mood disturbance and 
reduced physical functioning (So et al. 2009).   The reasons for this are 
unclear, however, it is likely that when patients receive cancer treatment, 
damage inevitably occurs to healthy cells and tissues, leading to treatment 
side-effects and symptoms.  Of the various symptoms, fatigue, pain, anxiety 
and depression are most prevalent among breast cancer patients and result 
in significant reductions in quality of life (So et al. 2009).   Importantly, sleep 
dysfunction may affect more than half of breast cancer patients and can be 
improved with exercise (Irwin, 2008a).  However, few studies have attempted 
to investigate sleep in a systematic way.  In addition to sleep problems, 
physical activity levels reduce significantly for many women after a diagnosis 
and remain low after treatment is complete (Irwin et al. 2003).  Explanations 
to account for these symptoms include biochemical changes secondary to 
disease and treatment, impaired nutritional status, psychosocial factors 
and/or mood disturbance (Sneider et al. 2007).    Exercise programmes have 
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been presented as a promising therapeutic strategy to address both the 
psychosocial and physical concerns of breast cancer patients.   
     
 
1.2  Current treatment options 
 
Current programmes in cancer settings are mostly limited to physical 
treatment addressing specific impairments caused by surgery or amputation 
(Irwin et al. 2003).  Such programmes do not usually deal with the 
psychosocial problems encountered by patients.  This is despite exercise 
being shown as a promising strategy for the treatment of these symptoms.  
Previous reviews support the role of exercise in attenuating these problems, 
(McNeely et al. 2006; Markes et al. 2006) however, the results are mixed and 
often hampered by methodologic limitations that limit interpretation of the 
results.  The most common limitations include the use of small convenience 
samples, which result in limited statistical power.  Wide variability in study 
interventions and outcome measures also make it difficult to compare results 
across trials.   
 
 
1.3  Exercise interventions  
 
Clinical trials of exercise in breast cancer patients primarily prescribe 
supervised, structured, and often gym-based exercise programmes that meet 
recommended guidelines.  Structured exercise interventions generally 
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require participants to attend a centre to exercise at a specified duration and 
frequency (e.g. 30 minutes four times per week).  Research in the general 
population indicates that structured exercise programmes are a difficult 
challenge for healthy adults and may be even more difficult after a cancer 
diagnosis and treatment (Markes et al. 2006).  To overcome these 
challenges researchers have developed home-based exercise programmes.  
Pinto et al. (2009), for example, found that home-based physical intervention 
successfully increased physical activity and psychological well-being among 
stage 0 to II breast cancer patients who had completed treatment.   However, 
sample size treatment fidelity issues and adherence may have limited 
results.  Despite these challenges, emerging evidence confirms that exercise 
interventions are beneficial for cancer patients and can help to improve both 
the psychological and physical problems following treatment (Fong et al. 
2012). 
 
Previous reviews (McNeely et al. 2006; Markes et al. 2006) included studies 
up to 2006 and most have focused on outcomes during breast cancer 
treatment.  The focus of the McNeeley et al. and Markes et al reviews were 
restricted to trials that focused on physical fitness outcomes and 
psychological distress during breast cancer treatment.  It is well known that 
the post-treatment period is an important time in terms of adjustment and 
personal change.  However, relatively few studies have focused on this 
transition.  There are now newer studies that focus on this time period, and 
therefore, there is sufficient research available to justify another review in this 
area.    A recent meta-analysis focusing on outcomes during and after 
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treatment found that exercise improved psychosocial functioning (Duijts et al. 
2011).  However, this review like many previous studies did not consider 
sleep as an outcome variable and included metastatic disease, which may 
have biased results.  To address these limitations, there is a need to update 
previous findings and examine trials published since 2006.  The rationale for 
considering exercise as an intervention to alleviate sleep and mood 
disturbance is based on the literature which demonstrates aerobic exercise 
has antidepressant and anxiolytic effects that protect against stress (Spiegal, 
1997).  Exercise has also been found to increase functional capacity leading 
to reduced effort and decreased fatigue (de Jong et al. 2002).  It is 
hypothesised that these combined effects may alleviate the psychosocial 
problems associated with cancer-related treatment.   
 
1.4  Aims and objectives 
 
The current review will address the following research questions: 
 
1) Are exercise interventions more effective for improving psychosocial 
outcomes (i.e., sleep, fatigue, depression, anxiety) following breast 
cancer treatment, when compared with established therapies in 
controlled trials? 
2) What are the methodological limitations of exercise intervention 
studies? 
3) Are there any adverse events associated with exercise interventions? 
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METHOD 
 
2.1  Search strategy for identification of studies 
 
The electronic databases from Ovid MEDLINE, Embase, The Cochrane 
Central Register for Controlled Trials and EBSCO databases (PsycINFO, 
CINAHL, Health Source: Nursing/Academic Section, PsycARTICLES, 
Psychology & Behavioural Sciences Collection) were searched from March 
2006 to April 2012. The search was supplemented by hand searching the 
reference sections of those papers which were deemed appropriate for 
inclusion, as well as those of relevant recent reviews (McNeeley et al. 2006; 
Markes et al. 2006; Fong et al. 2012; Duijts et al. 2011). 
 
 
2.2  Search terms 
 
Search terms included the following Medical Subject Headings (MeSH) 
[BREAST CANCER] with [EXERCISE*] or [PHYSICAL ACTIVIT*] and the 
terms linked to the subject headings: [BREAST NEOPLASMS] and 
[EXERCISE] or [EXERCISE THERAPY] and [SLEEP] and [FATIGUE] and 
[AFFECT].  For databases that did not use MeSH headings the search 
strategy was modified to include the following keywords: (1) (breast cancer)*; 
(2) (exercise* or physical activit*); (3) (intervention* or therapy* or train*); (4) 
(sleep); (5) (fatigue or mental fatigue); (6) (psychosocial or emotion* or 
distress* or affect or mood or anx*).  The symbol * denotes database 
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operators, which include truncations in the term to be included within the 
search.  These six searches were then combined using ‘AND’.    References 
were stored and managed using Reference Manager Software.   
 
2.3  Criteria for including and excluding studies 
 
A set of inclusion criteria was applied, regarding study type, participant 
characteristics, timing of recruitment, intervention and focus of main outcome 
variables, e.g. sleep, fatigue, depression, anxiety.  The review included 
English language articles and may therefore reflect selective publication bias 
of English language studies. 
 
1) Study type:    Randomised Controlled Trials. 
2) Participants: Women with stage 0-IIIa breast cancer, 
(excluding metastatic disease) following 
completion of adjuvant therapy (i.e. 
radiotherapy or chemotherapy) with the 
exception of hormonal therapy. 
3) Recruitment: 12-months post-treatment (as evidence 
shows that the majority of cancer patients 
prefer to start an exercise programme after 
they have completed initial treatment) 
(Jones & Courneya, 2002). 
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4) Intervention: Exercise therapy (including walking of 
moderate intensity and aerobic or 
resistance exercise). 
5) Outcomes: Measures related to psychosocial distress 
(i.e. sleep disturbance, fatigue, depression, 
anxiety). 
 
Exclusion criteria included: (1) research examining unpublished data; (2) no 
data, preliminary data or qualitative data; (3) review articles; (4) single case 
reports; (5) rehabilitation programmes with no specific intervention; (6) 
studies where time since completion of treatment was less than 12 months; 
(7) articles describing pharmacological interventions and, (8) articles 
presented in languages other than English.  Figure 1 illustrates the article 
selection for the review. 
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Figure 1.  Flow diagram of papers excluded at each stage of the review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Articles identified through 
electronic databases 
(n=1614) 
Articles identified by manual  
search of reference lists and 
screened for retrieval (n=9) 
Total articles (n=1623) 
1490 articles excluded on title 
alone, leaving 124 
98 articles excluded based on 
abstract, leaving 26 
 
26 full-text articles assessed 
for eligibility 
19 articles excluded: 
 
Participants receiving treatment 
(n=7) 
 
Not a randomised controlled trial 
(n=3) 
 
Participants not predominantly 
Stage 0-IIIa breast cancer (n=2) 
 
Qualitative data (n=1) 
 
Outcome variables not relevant to 
this review (n=4) 
 
No published data (n=1) 
 
Time since treatment <12 months 
(n= 1) 
 
 
 
 
 
 
 
7 articles rated for 
methodological quality using a 
specific set of criteria 
 
9 duplicates removed, leaving 
1614 
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2.4  Methodological quality assessment 
 
The Clinical Trials Assessment Measure (CTAM; see Appendix 1.1; Tarrier & 
Wykes, 2004) was used to assess the quality of trials.  The CTAM was 
chosen to ensure the scientific rigour of the review process, due to the 
thoroughness of its 15 included items and its use in previous systematic 
reviews of randomised controlled trials (Wykes et al. 2007).  Furthermore, 
the CTAM shows high inter-rater reliability and good criterion related validity 
when compared with other scoring systems.  The CTAM asks the rater to 
answer 15 questions about the study, under the headings of: sample, 
allocation, assessment, control groups, analysis and active treatment.  Each 
question is weighted and scores are summed to reach a total score out of a 
possible 100.  Studies are categorised as scoring high, moderate or low 
using the arbitrary grading system: 
 
 High score = >70% 
 Moderate score = 40-69% 
 Low score = <39% 
 
Studies were reviewed in a blinded manner by an independent rater.  Overall 
percentage agreement was high (94%).  Individual disagreements were 
resolved by discussion with the independent reviewer.   Effect sizes were 
calculated for the main outcome variables in five studies (Vallance et al. 
2007; Daley et al. 2007; Fillion et al. 2008; Milne et al. 2008; Rogers et al. 
2009) using Cohen’s d (Cohen, 1992; see Appendix 1.2 for calculation of 
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effect size).  Effect sizes were not computed for two studies due to 
insufficient information (Payne et al. 2008) and null findings (Cadmus et al. 
2009).   
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RESULTS   
 
3.1  Summary of results 
 
A total of 1,623 articles were initially identified from electronic databases and 
manual searches of reference lists.  Following removal of nine duplicate 
studies the literature search identified 1614 articles. Of these, 1,490 studies 
were excluded on the basis of title alone, mainly because they were not 
intervention studies or pharmacological intervention studies.  A further 98 
articles were excluded based on their abstract as they did not fulfil the 
specified inclusion and exclusion criteria.  Again, this was mainly because 
the studies did not relate to a direct intervention.  A full article search was 
performed on the remaining 26 studies, of which 19 were excluded (refs: 
Pinto et al. 2009; Badger et al. 2007; Basen-Engquist et al. 2006; Blacklock 
et al. 2010; Courneya et al. 2007a; Courneya et al. 2007b; Courneya et al. 
2008; Courneya et al. 2009; Hwang et al. 2008; Irwin et al. 2008b; Jones et 
al. 2010; Latka et al. 2009; Mayer et al. 2010; McClure et al. 2010; Mutrie et 
al. 2007; Ohira et al. 2006; Yang et al. 2011; Wang et al. 2011; Wu et al. 
2008) for reasons specified in Appendix 1.3.  Of the remaining seven 
included studies, one was rated as being of ‘high’ methodological quality, five 
were rated as ‘moderate’ and the remaining study as ‘low’ quality.  
Descriptions of the populations studied, intervention characteristics and 
study quality are summarised in Table 1.  Individual quality assessment 
ratings for included studies can be found in Appendix 1.4.   
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Table 1.  Description and methodological quality ratings of included studies 
Study and 
quality 
rating (%) 
Sample 
(N, age 
range, 
disease 
stage, time 
since 
treatment 
complete) 
 
Design Intervention Outcome 
measures
a
 
Effect Size 
(d) 
Follow-
up 
Findings Adverse 
events 
Limitations 
 
Daley et al 
(2007) 
 
71% 
High 
N=108 breast 
cancer 
patients 
 
Age 18-65 
years 
 
Stage I-III  
 
17.5 months 
post-
treatment   
RCT 
comparing 
the effects of 
exercise 
intervention 
vs. placebo 
vs. usual 
care. 
Supervised aerobic 
exercise 3 times a 
week for 8 weeks plus 
cognitive-behavioural 
techniques promoting 
exercise behaviour 
change. 
 
2 intervention groups: 
Supervised aerobic 
exercise vs. exercise 
placebo (body 
conditioning) vs. usual 
care (control). 
 
Fatigue, 
RPFS 
 
Depression, 
BDI-II 
 
QoL, FACT-G 
and FACT-B 
 
Exercise 
behaviour, 
self-report. 
 
Aerobic 
fitness, 
treadmill 
walking test  
 
Depression: 
d=0.24 
small 
 
QoL: 
FACT-G 
d=0.69 
medium to 
large at 8 
wk follow-
up. 
FACT-B 
d=0.72 
large 
8, 12 
wks 
No group 
differences for 
fatigue at follow-
up. 
 
Both intervention 
groups reported 
lower 
depression 
scores 
compared to 
control group. 
 
QoL significantly 
improved in the 
supervised 
aerobic exercise 
group compared 
to usual care at 
both follow-ups. 
 
Aerobic fitness 
improved in both 
intervention 
groups. 
 
Not 
assessed/reported 
upon 
Intervention 
contamination in  
the exercise-
placebo and 
control group. 
 
Possible 
Hawthorne effect 
- blinding of 
assessments not 
possible. 
 
Possibility of 
Type I error - trial 
underpowered 
and no 
adjustments 
made for multiple 
comparisons. 
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Vallance  
et al (2007) 
 
68% 
Moderate 
N=377 breast 
cancer 
patients 
 
Age 30-90 
years 
 
Stage I-IIIa 
breast cancer 
 
39 months 
post-
treatment 
RCT 
comparing 
the effects of 
print materials 
and step 
pedometers 
vs. control. 
30mins moderate / 
vigorous physical 
activity 5 days a week 
for 12-weeks using 
step pedometer  / 
breast cancer- specific 
print materials.   
 
 
3 intervention Groups: 
Pedometer group 
(PED) vs. Print 
Material (PM) vs. 
Combination of Step 
Pedometer and Print 
Material (COM) vs. 
Standard 
Recommendation (SR; 
control).  
 
Fatigue, 
FACT-B scale 
 
Physical 
activity and 
pedometer 
 
Aerobic 
fitness, 
treadmill 
walking test  
Fatigue: 
d=0.37 
small to 
medium 
 
Physical 
activity: 
PM  d=0.25 
small 
 PED  
d=0.37 
medium 
COM 
d=0.38 
Medium 
3 mths COM group 
reported 
improved fatigue 
compared to SR 
group. 
 
All 3 intervention 
groups showed 
significant 
increases in 
physical activity 
compared to SR 
group. 
 
 
 
 
Not 
assessed/reported 
upon 
No objective 
measure of 
physical activity, 
self-report only. 
 
Possibility of 
Type I error - no 
corrections made 
for multiple 
comparisons. 
 
Failure to blind  
participants from 
pedometer step 
count during 
baseline and 
post-intervention. 
Fillion et al 
(2008) 
 
58% 
Moderate 
N=87 
 
Age≥18 years 
 
Stage 0-III 
 
24 months 
post-
treatment 
RCT 
comparing 
group 
intervention to 
usual care. 
Group intervention 
using stress/fatigue 
management , walking 
exercise of moderate 
intensity, muscle-
relaxation and 
telephone booster 
session, once a week 
for 4-wks vs. usual-
care. 
Fatigue, MFI 
 
Emotional 
distress, 
POMS anxiety 
and 
depression 
 
QoL, SF12 
 
Fitness, 
treadmill 
walking test 
 
Subjective 
physical 
activity, self-
administered 
Fatigue: 
d=0.48 
medium 
at 3-mth 
follow-up 
 
Emotional 
distress: 
d=0.46 
medium 
4, 12 
wks 
Intervention 
group showed 
significant 
reductions in 
fatigue and 
emotional 
distress at 12wk 
follow-up 
compared to 
control group. 
 
Fitness 
improved 
equally in both 
groups. 
 
 
Not 
assessed/reported 
upon 
Multilevel aspect 
of intervention 
made it difficult to 
determine which 
aspects of the 
intervention were 
effective. 
 
Adherence to 
walking 
programme not 
assessed - limits 
comparisons and 
generalisability. 
 
Non-specific 
therapeutic 
effects. 
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questionnaire 
 
Objective  
physical 
activity, 
actigraph 
 
 
Questionnaire 
measuring 
subjective 
physical activity 
not standardised. 
 
Low participation 
rate. 
Milne et al 
(2008) 
 
58% 
(Moderate) 
N=58 
 
Age ≥18 
years 
 
Stage I-II 
breast cancer 
 
13 months 
post-
treatment  
 
 
RCT 2-armed 
complete 
crossover 
design 
comparing 
immediate vs. 
delayed 
exercise 
programme. 
Supervised aerobic 
and resistance 
exercise training 3 
times a week for 12 
weeks. 
 
2 intervention groups: 
Immediate Exercise 
Group (IEG) 
completed the 
exercise program from 
baseline to 12 weeks 
vs. Delayed Exercise 
Group (DEG) 
completed the 
exercise programme 
from 13 to 24 weeks 
Fatigue, 
SCFS 
 
Social 
Physique 
Anxiety, SPAS 
 
QoL, FACT-
B;FACT-G 
scale 
 
Aerobic 
fitness, cycle 
test 
 
 
Fatigue: 
d=0.42 
medium 
 
QoL: 
FACT-B 
d=0.52 
medium 
at 3-mth 
follow-up. 
FACT-G 
d=0.46 
medium 
6, 12, 
18, 24 
wks 
Fatigue scores 
improved in the 
IEG compared 
to no change in 
the DEG.  From 
weeks 12 to 18 
fatigue improved 
in the DEG. 
 
QoL significantly 
increased in the 
IEG compared 
to a reduction in 
the DEG. 
 
Aerobic fitness 
improved in both 
intervention 
groups. 
 
Not 
assessed/reported 
upon 
Therapist 
expectancy 
effects.  
 
Long-term 
treatment gains 
for fitness not 
known as 
participants 
assessed at post-
intervention only.  
 
Low adherence 
rate to exercise 
programme. 
 
Intervention 
quality not 
assessed. 
Rogers  
et al (2009) 
 
56% 
Moderate 
N=41 
 
Age 18-70 
years 
 
Stage I-IIIa 
 
33 months 
post-
RCT 2-armed 
comparing  
intervention to 
usual care. 
Multi-disciplinary 
physical activity 
behaviour change 
intervention 
incorporating walking 
of moderate intensity, 
stress management, 
counselling and role 
modelling, on an 
Fatigue, 
FACT-F 
 
Sleep, PSQI 
 
Objective 
physical 
fitness, 
actigraphy 
Physical 
activity: 
d=0.64 
medium to 
large. 
3mths No significant 
improvements in 
fatigue or sleep 
in the 
intervention 
group compared 
to control. 
 
Improved fitness 
No adverse events 
reported however  
intervention group 
reported greater 
increase in joint 
stiffness.   
 
Some non-serious 
events were 
PSQI sleep 
disturbance scale 
not included in 
data collection. 
 
Measurement 
bias - assessors 
not blind to group 
allocation. 
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treatment individual and group 
format, once a week 
for 12 wks vs. usual 
care. 
 
 
 
Self-reported 
physical 
activity, 
GLTEQ 
 
QoL, FACT-B 
and FACT-G 
 
 
and social 
wellbeing in the 
intervention 
group. 
 
 
recorded e.g. 
wheezing requiring 
physician evaluation 
for asthma, sinusitis, 
back pain related to 
falling 
 
Study outcomes  
influenced by 
different exercise 
specialists. 
 
 
Cadmus  
et al 
(2009) 
 
55% 
Moderate 
N=75 
 
Age 34-79 
years 
 
Stage 0-IIIa 
 
12 months 
post-
treatment 
 
RCT 
comparing 
supervised 
exercise 
intervention to 
usual care. 
 
 
Supervised 
intervention of 
moderate to vigorous 
physical activity 3 
times a week for 6-
mths vs. home-based 
exercise among breast 
cancer patients vs. 
usual care. 
 
 
Depression, 
CES-D 
 
Anxiety, STAI 
 
QoL: FACT-B 
 
Physical 
fitness, 
Physical 
Activity Log 
 
 6 mths No 
improvements 
were found on 
measures of 
depression and 
anxiety in the 
intervention 
group compared 
to control. 
 
 
Assessed and none 
reported. 
Small sample 
size. 
 
No formal power 
calculation. 
 
Possible self-
selection bias as 
most participants 
were higher 
functioning than 
overall population 
of breast cancer 
patients.  
 
Payne et al 
(2008) 
 
19% 
Low 
N=58 
 
Age 55- 78 
years 
 
Stage of 
disease and 
time since 
treatment not 
reported. 
Contacted 
study author 
who 
RCT 
comparing 
home-based 
walking 
exercise with 
usual care. 
Home-based 
moderate walking 
activity for 20 mins 4 
times a week. 
Sleep, PSQI 
 
Fatigue, PFS 
 
Depressive, 
CES-D 
 
Exercise, self-
assessed 
activity log 
Not 
reported. 
 
Effect size 
could not be 
calculated. 
2, 12, 
14 wks 
Intervention 
group reported 
better sleep 
compared to 
usual care. 
 
No significant 
differences 
between groups 
on measures of 
fatigue and 
depression. 
 
Not 
assessed/reported 
upon 
Small sample 
size may have 
reduced power. 
 
No details of 
randomisation 
procedures. 
 
No blinding. 
 
Adherence to 
study parameters 
not assessed. 
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confirmed 
stage I-III and 
minimum 12 
mths post-
treatment. 
  
Treatment fidelity 
not assessed. 
 
Reliance on self-
reported physical 
activity despite 
objective 
measure 
(actigraph and 
step 
pedometers). 
 
a
Outcome Measures: BDI-II=Beck Depression Inventory; CES-D=Centres for Epidemiological Studies-Depression Scale; FACT-B=Functional assessment of 
cancer therapy-breast; FACT-F=Functional Assessment of Cancer therapy-Fatigue; FACT-G=Functional assessment of cancer therapy-general; 
GLTEQ=Godin Leisure-Time Exercise Questionnaire; MFI=Multidimensional Fatigue Inventory; PFS=Piper Fatigue Scale; PSQI=Pittsburgh Sleep Quality 
Index; POMS=Profile of Mood States; RPFS=Revised Piper Fatigue Scale; SCFS=Schwartz Cancer Fatigue Scale; SPA=Social physique anxiety; 
STAI=State-Trait Anxiety Index.
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3.2  Study characteristics 
 
All the studies used a randomised controlled design.  Participants were 
women ≥18 years of age with stage 0-IIIa breast cancer who had completed 
adjuvant therapy.  Sample size ranged from 41 participants (Daley et al. 
2007) to studies containing 377 breast cancer patients (Vallance et al. 2007).   
The mean length of time since completion of treatment was 21.5 months.  A 
variety of physical exercise modalities were employed, which differed in type: 
walking (Fillion et al. 2008; Rogers et al. 2009; Payne et al. 2008), aerobic 
resistance exercise (Vallance et al. 2007; Daley et al. 2007; Fillion et al. 
2008; Milne et al. 2008; Cadmus et al. 2009), muscle strengthening (Payne 
et al. 2008) or combined exercise (e.g. physical activity plus cognitive 
behavioural techniques; Daley et al. 2007; Fillion et al. 2008; Rogers et al. 
2009), intensity, with most programs at 75 per cent to 85 per cent of the 
estimated maximal heart rate (Vallance et al. 2007; Daley et al. 2007; Fillion 
et al. 2008; Payne et al. 2008; Cadmus et al. 2009); frequency, which ranged 
from once a week to five days a week; and duration, ranging from four to 12 
weeks.  Interventions were delivered on an individual (Vallance et al. 2007; 
Daley et al. 2007; Rogers et al. 2009; Payne et al. 2008; Cadmus et al. 2009) 
or group basis (Fillion et al. 2008; Milne et al. 2008; Rogers et al. 2009) and 
some were supervised (Vallance et al. 2007; Daley et al. 2007; Fillion et al. 
2008; Milne et al. 2008; Rogers et al. 2009; Cadmus et al. 2009) or 
unsupervised (Vallance et al 2007; Payne et al. 2008).  Examples of control 
or comparison group activities included body conditioning exercises 
(Cadmus et al. 2009), exercise of a lesser intensity (Rogers et al. 2009) and 
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usual care (Daley et al. 2007; Fillion et al. 2008; Rogers et al. 2009; Payne et 
al. 2008; Cadmus et al. 2009).  In one study, the comparison group 
participated in a cross-over trial (Milne et al. 2008).  Of the two studies that 
measured sleep, Payne et al. found improvements in sleep, whereas Rogers 
et al. found no differences between groups.  Mixed results were found for the 
effect of exercise on fatigue, with three studies reporting significant 
improvements in fatigue (Vallance et al. 2007; Rogers et al. 2009; Payne et 
al. 2008) and three finding no differences between groups (Fillion et al. 2008; 
Rogers et al. 2009; Payne et al. 2008).  Four studies investigated the effects 
of exercise on psychological distress (depression; Daley et al. 2007; Fillion et 
al. 2008); anxiety/depression (Fillion et al. 2008; Cadmus et al. 2009), with 
two finding improvements in depression (Daley et al. 2007; Fillion et al. 2008) 
and anxiety (Fillion et al. 2008) and two finding no difference between groups 
(Payne et al. 2008; Cadmus et al. 2009).  Adverse events related to the 
intervention were assessed in two studies (Rogers et al. 2009; Cadmus et al. 
2009).  No adverse events were reported, however, the intervention group in 
one study reported a significant increase in joint stiffness (Rogers et al. 
2009).  
 
3.3  High quality studies 
 
Daley et al. examined the effects of aerobic exercise on fatigue and 
depression in women treated for breast cancer, relative to usual care.  A 
small benefit for depression was noted in the intervention group (d=0.24).  
No group differences were found for fatigue at follow-up.  This paper is of 
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particular high methodological quality and scored the highest rating of all 
included studies.  Strengths of this study included the inclusion of baseline 
data, the use of an appropriate comparison group, low attrition and good 
adherence rates, detailed descriptions of the intervention components and 
how these were standardised.  Blinded assessments of outcomes, however, 
were not a feature of this study and may have biased the results.  Lastly, as 
no adjustments were made for multiple comparisons, the risk of Type I errors 
increased. 
 
3.4  Moderate quality 
 
Vallance et al. studied the effects of breast cancer print materials and step 
pedometers on fatigue levels.  Participants were randomly assigned to one of 
four groups: standard public health recommendation for physical activity 
(SR), print materials (PM), step pedometer (SP) or a combination of PM and 
SP (COM). The COM group showed the greatest benefits for fatigue, 
compared to the SR group, with a small to medium effect size noted 
(d=0.37).  Methodological strengths included a large sample size, the use of 
a SR as a comparison group, high fidelity to the intervention and minimal 
loss to follow-up.  The study was limited, however, by the use of self reported 
physical activity, failure to blind participants during step pedometer counts 
and potential false positive findings. 
 
Fillion et al. examined the effectiveness of a combined stress management 
and physical activity intervention on fatigue and emotional distress (i.e. 
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anxiety and depression). Participants were randomly assigned to either the 
group intervention or usual-care.  Improvements in fatigue and emotional 
distress were found in the intervention group compared to the control group, 
with medium effect sizes noted (d=0.48; d=0.46).  Study limitations included 
the multilevel aspect of the intervention, which made it difficult to determine 
which aspects of the intervention were effective.  Non-specific effects of 
therapy (i.e. participants in the intervention group spent more time [one-third] 
with study experts than the control group) and the low participation rate, may 
also have limited group comparisons and generalisability. 
 
Milne et al. studied the effects of a combined aerobic and resistance 
programme on fatigue and social physique anxiety.  A particular strength of 
this trial was the complete crossover design, which meant that participants in 
the immediate exercise group (IEG) completed the exercise programme from 
baseline to 12 weeks.  The delayed exercise group (DEG) completed the 
intervention from 13 to 24 weeks.  Reductions in fatigue were found in the 
IEG from baseline to week 18 and in the DEG from week 12 to 18, with a 
medium effect size that was statistically significant (d=0.42).  However, the 
same professionals treated both groups, therefore, expectancy effects may 
have biased the results.   
 
Rogers et al. examined the effectiveness of a combined intervention on sleep 
and fatigue.  Participants were randomly assigned to either a 12-week 
physical activity intervention or usual care.  No significant differences were 
found between groups on measures of sleep or fatigue.  Limitations of the 
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study included non-blinding of participants, increased attention with study 
staff in the intervention group and the omission of the sleep disturbance 
scale, which may have contributed to a floor effect.  Despite these limitations, 
the study had several strengths, including the use of an objective measure of 
physical activity, assessment of intervention adherence and monitoring 
adverse events, of which none were reported.  
 
Cadmus et al. examined the effects of a 6-month supervised exercise 
intervention on anxiety and depression, relative to usual care. The 
intervention consisted of supervised moderate/vigorous exercise sessions 
three times a week, at a local health club and an additional two days, either 
at the health club or in the participants’ home.  Participants assigned to usual 
care were told that they could exercise on their own if they chose to do so.  
Exercise was not associated with improvements in anxiety or depression.  To 
explain these findings, the authors suggest that high levels of psychological 
well-being at the time of enrolment may have made increases difficult to 
obtain.  The authors attempted to tease this out by conducting secondary 
analyses on participants who scored in the bottom 50 per cent on each 
measure, however, no effect of the intervention was found.  Despite good 
adherence rates, the sample size was small which meant the trial may have 
been underpowered and as this was a pilot study, no formal power 
calculation was conducted.  In addition, no data was collected on ineligible or 
uninterested participants, may have led to selection bias.  
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3.5  Low quality 
 
In this pilot study, Payne et al. examined the effects of a home-based 
walking intervention on fatigue, sleep disturbance and depressive symptoms, 
compared to usual care.  Improvements in sleep were found in the 
intervention group, however, no significant differences were found between 
groups on measures of fatigue or depression.  This study had numerous 
methodological flaws including small sample size (n=20), no information on 
concealment of allocation or randomisation procedures, high attrition rates 
and the use of subjective measures of physical activity, despite having 
objective data.  The intervention was poorly described and data analysis did 
not include the “intention-to-treat” strategy.  In addition, as this was a home-
based intervention study, treatment fidelity tracking issues were an issue.   
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DISCUSSION 
 
4.1  General findings 
 
This review provides mixed evidence for the effects of exercise interventions 
in improving sleep, fatigue and mood after completion of breast cancer 
treatment.  In general, the results suggest that a combined intervention 
approach (i.e., cognitive-behavioural strategies and physical activity) may be 
more effective than either approach alone.  This may be because a 
combined approach addresses both the emotional and physical impact of 
breast cancer, which is important, as we know that the emotional impact of 
cancer can continue long after physical symptoms have improved (Irwin et al. 
2008).   Seven studies included in the review were of variable quality with 
only one considered to be of high quality (Daley et al. 2007).  Of the two 
studies that investigated sleep, improvements were found in one study 
(Payne et al. 2008), however, due to significant methodological flaws, the 
results of this study should be interpreted with caution.  Improvements in 
fatigue (Vallance et al. 2007; Fillion et al. 2008; Milne et al. 2008) were 
consistent with a recent meta-analysis by Duijts et al., which demonstrated 
moderate effect sizes between exercise and fatigue.  The lack of effect in 
other studies may be related to low fatigue scores at baseline which caused 
a floor effect (Daley et al. 2007; Rogers et al. 2009; Payne et al 2008).  
Future studies should consider focusing inclusion criteria or enrolling an 
adequate sample size to assess intervention effects on the basis of time 
since treatment or cancer stage (Courneya et al. 2007b).   
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The finding of improvements in depression is consistent with previous 
research (McNeeley et al. 2006), though effect sizes were small.  High levels 
of functioning at the time of enrolment or lack of power may have explained 
the null findings on measures of psychological distress in the other studies 
included in the review.  Only two studies assessed and reported adverse 
events (Rogers et al. 2009; Cadmus et al. 2009).   Future RCTs should 
formally monitor and report the incidence of potential adverse events as 
requested by the CONSORT checklist (Moher et al. 2001), as this data could 
help to inform interventionists identify and overcome potential barriers to 
adherence.  Despite some evidence that exercise interventions are cost-
effective in various medical conditions, the number of studies among breast 
cancer patients is limited and requires further investigation (Roine et al. 
2009).  
 
 
4.2  Methodological limitations of included studies 
 
Overall, the trials in this review were of moderate methodological quality.  
The most common methodological problems were with blinding (Vallance et 
al. 2007; Daley et al. 2007; Rogers et al. 2009; Cadmus et al. 2009) and 
intervention contamination (Daley et al. 2007; Fillion et al. 2008; Milne et al. 
2008; Payne et al. 2008).    Blinded assessment of outcome is possible in 
RCTs but unfortunately was not a feature in most of the studies in this 
review.  Furthermore, the improvements observed in some studies may be 
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the result of intervention contamination and reflect benefits accrued from 
group activities and fellow patients, rather than the intervention itself. 
 
 
4.3  Strengths, limitations and future research 
 
To the author’s knowledge, this is the first systematic review to focus 
specifically on sleep dysfunction following breast cancer treatment.  The 
limited evidence for the effects of exercise on sleep is not surprising, given 
that only four of the 26 eligible studies, measured sleep as an outcome.  Until 
the volume of literature expands in this area, it is not possible to summarise 
the evidence for the efficacy of exercise on sleep problems.  The review 
highlights a lack of consistent evidence for the efficacy of exercise in 
improving psychosocial outcomes after treatment for breast cancer.  A 
potential explanation for these findings relates to treatment stage and 
variation in intervention type.  Future reviews should consider focusing on 
patient-specific and treatment-specific factors, as well as key characteristics 
of interventions that clearly differ between studies.  Limitations of the current 
review include the variability in outcome measures and interventions used.  
Future RCTs should consider standardising both the mode and intensity of 
exercise used and use a comparable set of outcome measures, as this will 
allow pooling of data and comparisons across studies.   
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4.4  Conclusions and implications for NHS policy and practice 
 
In conclusion, the current literature provides some evidence that a combined 
intervention approach may be more effective in improving psychosocial 
outcomes after breast cancer treatment, than stand alone approaches.  
Future studies with appropriate comparisons of different intervention 
elements are needed to support practitioners in clinical decision-making.  
There is also a need to increase the evidence base on sleep problems 
following breast cancer treatment as this is a much neglected area.  Disease 
and treatment-related symptoms can be intense and lead to significant 
complications that result in reduced psychosocial and physical functioning.  
Based on the results of this review, integrating psychological strategies into 
exercise interventions may be necessary to strengthen the effect of exercise 
in reducing interference with daily life caused by treatment side-effects.  
Finally, the adoption of exercise as a standard treatment recommendation for 
breast cancer patients may allow for the above methodological problems to 
be addressed. 
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LAY SUMMARY 
 
We know that many women who have had treatment for breast cancer 
experience a range of symptoms which affects their quality of life.  Sleep 
problems, fatigue, anxiety and depression are just some of the symptoms 
following treatment.  Exercise has been shown to improve some of these 
symptoms.  However, many patients do not perform regular physical activity 
after treatment is complete.  We were interested in the link between activity 
levels and these symptoms.  We collected information about physical activity 
and common symptoms such as sleep problems, fatigue, anxiety and 
depression.  The results of our study show that most patients were relatively 
active, but only a few were sufficiently active to meet national guidelines.  We 
also found that activity was not related to sleep, fatigue or depression.  There 
was a positive relationship between anxiety and high levels of activity, 
indicating that anxiety increased with more vigorous exercise.  This 
information is important as it may help health professionals to target anxiety 
and include increased physical activity as a component of patients’ post-
treatment symptom management. We hope this will lead to improved 
services for cancer patients and help facilitate good post-treatment 
functioning. 
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ABSTRACT 
 
Objective: Physical activity has been shown to improve sleep, fatigue and 
mood among breast cancer patients during treatment.  However, few studies 
have focused on assessing the effect of activity on these symptoms after 
treatment is complete.  Using a correlational design, this study aimed to 
explore associations between physical activity, sleep, fatigue and mood in 
women who had completed treatment for breast cancer and to evaluate the 
reliability and validity of the short-version International Physical Activity 
Questionnaire.  
Methods: Twenty-eight women (aged 43 to 75 years) with stage I and II 
breast cancer were recruited at 6-months post-diagnosis and after 
completion of active treatment.  Respondents completed measures of 
activity, sleep, fatigue, depression and anxiety.  Six participants also 
undertook actigraphic monitoring to obtain objective activity levels.   
Results: Descriptive analyses suggest the sample was relatively active with 
50% of participants engaging in moderate-intensity activities.  Despite this, 
however, only 18% were sufficiently active to meet national guidelines.  No 
significant relationships were found between total physical activity, sleep, 
fatigue or depression, whereas, anxiety and activity were significantly 
correlated.  Reliability of the IPAQ was low, however, comparison with 
objective actigraphy data suggests high criterion validity.   
Conclusion: These findings have implications for designing interventions to 
reduce anxiety among breast cancer patients returning to physical activity 
46 
 
after treatment.  However, the choice of assessment instrument may have a 
significant impact on research results.  
 
Keywords: breast cancer; physical activity; sleep; fatigue; depression; 
anxiety. 
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INTRODUCTION 
 
1.1  Breast cancer and symptom distress  
 
Breast cancer is the most commonly occurring cancer among women in the 
United Kingdom.  More than 40,000 new cases are reported each year and 
this figure is expected to rise1.  However, with advances in treatment and 
management, survival rates are increasing.  Surviving cancer usually means 
enduring sequential combinations of treatment modalities which can result in 
significant reductions in quality of life.2  During and after breast cancer 
treatment, many patients experience unpleasant side-effects such as weight 
gain, sleep disturbance, fatigue and depression.3  Exercise has been shown 
to be effective in preventing weight gain and alleviating fatigue and 
depression.4,5   However, there is a lack of research looking directly at the 
role of exercise in reducing sleep disturbance following breast cancer 
treatment.6   This is surprising, considering 38% of breast cancer patients 
experience persistent sleep disturbance, with distress being a significant 
contributor.7   
 
1.2  Physical activity levels in breast cancer patients 
 
Despite the benefits of exercise, a large proportion of breast cancer patients 
do not perform regular physical activity or meet recommended physical 
activity guidelines.8  Similarly, many patients decrease their activity after 
diagnosis, highlighting the need for intervention.9   Evidence shows that 
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these decreases are related to the type of cancer treatment patients receive, 
with the greatest decrease in activity found among women who are treated 
with radiation and chemotherapy (50%), compared to women who undergo 
surgery only (24%).10  Other reasons include that women are fearful of 
overexertion or uncertain of what they can do while receiving treatment.11  A 
lack of medical advice12 or reluctance of oncologists to prescribe exercise 
may also explain low activity levels.13  Another reason may be that patients 
lack the confidence or self-efficacy to engage in exercise.14  Self-efficacy is 
used within social cognitive theory (SCT) and provides a useful framework 
for understanding some of the barriers to exercise participation.15  For 
example, if an individual feels confident that they can successfully engage in 
a behaviour, he or she is more likely to engage in that activity, and 
interventions that improve self-efficacy increase behaviour compliance.  A 
prospective study evaluating SCT demonstrated the importance of self-
efficacy for exercise adherence among breast cancer patients.16  Although 
the current study did not evaluate specific SCT constructs per se, poor self-
efficacy may suggest a mechanism to help explain reductions in activity 
following breast cancer treatment.   
 
 
Previous reviews of the effects of exercise on breast cancer patients report 
mixed results for improvements in sleep, fatigue and emotional quality of life.  
Courneya and Friedenreich,2 for example, found exercise to be associated 
with small but statistically significant improvements in fatigue and mood.  
However, a Cochrane review of exercise interventions exclusively during 
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treatment for breast cancer, found no improvements in fatigue or mood and 
limited evidence for an effect of exercise on sleep disturbance.17  Although 
some findings were positive, most of these trials had methodological 
limitations.  For example, most recruited small samples (e.g. fewer than 50 
participants), used convenience-sampling approaches and recruited cancer 
patients into non-randomised trials of short duration (e.g. less than 3 
months).  The majority also focused on the effects of exercise during breast 
cancer treatment.  Relatively few have focused on outcomes after treatment.  
Importantly, few trials have included sleep as an outcome variable.  In one 
study, Humpel and Iverson,18 examined the relationship between sleep 
disturbance and physical activity following a cancer diagnosis.  This was a 
questionnaire-based study in which 32 breast and 59 prostate cancer 
patients completed questionnaires measuring sleep quality, physical activity 
and fatigue.  The results showed that breast cancer patients experienced 
more sleep problems (48%) and greater fatigue (65%), compared to prostate 
cancer patients (17% and 43.%, respectively).  The results also suggest 
lower levels of activity among those reporting poor sleep.  However, the 
inclusion of both breast and prostate cancer patients limits interpretation of 
the results.  
 
1.3  Measuring physical activity 
 
Another challenge in the exercise literature is the measurement of physical 
activity.  There are numerous methods (objective and subjective), each with 
characteristic advantages and disadvantages.  Objective measures such as 
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heart rate and motion sensor monitoring can provide very detailed accurate 
measurement of physiological variables (which can be converted into 
relevant units such as energy expenditure) and have been shown to be 
highly reliable and valid measures of physical activity (Cronbach’s  α > .80).19  
However, the equipment involved in these studies can often be expensive 
making the cost of large-scale studies prohibitive.  The use of diary and 
recall methods are commonplace subjective forms of measuring physical 
activity, as they are relatively cheap to produce and easy to administer.  
However, a recent review highlighted the need for researchers to tackle the 
area of validating and standardising existing tools.20  The International 
Physical Activity Questionnaire (IPAQ) has been shown to be quick and easy 
to complete in a variety of situations (including postal methods).  It has been 
shown to be reliable and hold reasonable concurrent validity, however, 
further work is required to examine the criterion validity.21   
 
1.4  Aims and Hypotheses 
 
The current study aimed to: (1) examine associations between physical 
activity, sleep, fatigue and mood in women who had completed treatment for 
breast cancer; (2) evaluate the test-retest reliability of the IPAQ and, (3) 
examine the criterion validity of the IPAQ by comparing objective levels of 
activity (actigraphy) with self-reported activity scores (IPAQ) over a 3-week 
period. 
 
53 
 
The following predictions were made: (1) lower levels of physical activity, as 
measured by the IPAQ would be related to poorer sleep quality, as 
measured by the Insomnia Severity Index; (2) lower levels of physical activity 
would be related to higher levels of fatigue, as measured by the Fatigue 
Severity Scale; (3) lower levels of physical activity would be related to higher 
levels of anxiety and depression, as measured by the Hospital Anxiety and 
Depression Scale; (4) time 1 (T1) IPAQ scores would correlate with time 2 
(T2) and time 3 (T3) IPAQ scores; and (5) self-reported physical activity 
scores, as measured by the IPAQ would correlate with objective activity data, 
as measured by actigraphy. 
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METHOD 
 
2.1  Design 
 
A cross-sectional correlational design was used for the primary analyses.  
Relationships between physical activity and sleep were examined, while 
controlling for the effects of fatigue and mood.  Secondary analyses included 
correlations to examine the reliability of IPAQ scores over a 3-week period.  
Objective data from actigraphy was compared with self-reported levels of 
physical activity. 
 
2.2  Participants 
 
Participants were female, aged 18 years or older, with stage 0-IIIa breast 
cancer.  All participants had completed treatment for breast cancer 
(chemotherapy and radiotherapy) with the exception of hormonal therapy.  
Participants were recruited at six months following diagnosis once active 
treatment was complete.  Participants were excluded if they had an 
estimated prognosis fewer than six months, confusional problems or drug 
misuse, evidence of another sleep disorder or an untreated psychiatric 
disorder.  Potential participants were attending and recruited from follow-up 
clinics at the Beatson West of Scotland Cancer Centre and NHS satellite 
sites between December 2011 and April 2012.   
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2.3  Measures 
 
(i) International Physical Activity Questionnaire 
 
The primary outcome was physical activity, which was measured using the 
short-version IPAQ (Appendix 2.1).21   The IPAQ is a 4-item self-report 
instrument which measures physical activity over the preceding week. The 
short-version IPAQ was selected for use in this study as it is designed for 
monitoring purposes and is less burdensome than the long-version IPAQ, 
which is recommended for use in intervention studies.  The IPAQ assesses 
three specific types of activity: (a) walking (b) moderate-intensity activities 
and (c) vigorous-intensity activities.  The IPAQ counts only sessions lasting 
10 minutes or longer.  This reflects current scientific evidence that the 
physiological changes associated with health benefits from physical activity 
require a minimum duration.22  An additional question measured time spent 
sitting which was used as an indication of sedentary time.  The items on the 
IPAQ are structured to provide separate scores on walking, moderate-
intensity and vigorous-intensity activity.  The measure has been validated 
with breast cancer patients and demonstrates acceptable psychometric 
properties that are comparable to other established self-report 
questionnaires (Cronbach’s  α = .80) .23 
 
Computation of the total score requires summation of the duration in minutes 
and/or frequency (days) of walking, moderate-intensity and vigorous-intensity 
activities (expressed as ‘activity minutes’).  Algorithms are used to classify 
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three levels of physical activity into low, moderate or high categories.  Each 
activity on the questionnaire is assigned a metabolic equivalent task (MET) 
score based on the classification by Ainsworth et al.24  MET scores for 
specific activities are defined as the ratio of the metabolic rate associated 
with that activity divided by the resting metabolic rate.  For example, walking 
at an average pace is assigned a MET score of 3.3; moderate intensity 
activities such as jogging, 4; and vigorous intensity e.g. running, 8.  The 
MET-minutes per week (min/wk) was used in addition to ‘activity minutes’ 
because the total energy expenditure, rather than the time spent in specific 
exercise intensities is associated with improvement in health outcomes.22   
The scores for MET-min/wk for each activity were calculated from the 
reported minutes per day engaged in that activity multiplied by the assigned 
MET score.  The values from the individual activities were summed for a total 
MET-min/wk score.  For the sitting question, ‘Minutes’ was used as an 
indicator to reflect time spent in sitting rather than MET-minutes which would 
suggest an estimate of energy expenditure.  See Appendix 2.2 for IPAQ 
Scoring Protocol and cut-off values.   
 
(ii) Activity monitor (actigraphy) 
 
Objective measures of physical activity were recorded in a subsample of 
participants using actigraphy (Cambridge Neurotechnology Ltd).19  The wrist 
actiwatch is a nonintrusive device that records movement for 1-minute 
epochs through a wrist-watch microprocessor that senses motion (see 
Appendix 2.3 for an illustration of an actiwatch).  The actiwatch provides 
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activity/rest variables which include mesor to represent overall mean activity 
levels.  The sum of accelerations is transformed into counts.   Total activity 
was expressed as counts per recorded time (count-mins week-1) and 
compared with self-reported MET-minutes from the IPAQ (MET-mins  
week-1).       
 
 
(iii) Insomnia Severity Index 
 
Sleep quality was measured using the Insomnia Severity Index (ISI; 
Appendix 2.4).25  The ISI is a 7-item self-report questionnaire and is 
considered to be a core assessment tool in insomnia research studies. Each 
item is rated on a 0-4 scale, with total scores ranging from 0 to 28.  Higher 
scores indicate more severe insomnia.  Scores of between 8 and 14 indicate 
‘sub-threshold insomnia’; scores of 15-21 indicate ‘moderate insomnia’ and 
scores of 21-28 indicate ‘severe insomnia’. The instrument has demonstrated 
good psychometric properties with cancer patients in previous studies 
(Cronbach’s  α = .90).26 
 
 
(iv) Fatigue Severity Scale 
 
Fatigue was measured using the Fatigue Severity Scale (FSS; Appendix 
2.5).27  The FSS was originally developed as a tool to assess fatigue in 
patients with multiple sclerosis. The questionnaire has nine statements 
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enquiring about the severity of fatigue symptoms over the preceding week. 
Participants are asked to rate their level of agreement (toward seven) or 
disagreement (toward zero) with the nine statements.  A score of 36 and 
above (out of a maximum of 63) indicates the presence of significant fatigue. 
The FSS has demonstrated excellent validity and reliability in a number of 
other studies of patients with medical conditions and sleep disorders 
(Cronbach’s  α = .94) .28  
 
(v) Hospital Anxiety and Depression Scale 
 
Anxiety and depressive symptoms were measured using the Hospital Anxiety 
and Depression Scale (HADS; Appendix 2.6).29 The HADS is a brief 14-item 
self-report measure, which is widely used to assess anxiety and depression 
in patients with medical conditions.  The scale is quick and easy to 
administer and consists of two subscales of seven items designed to 
measure levels of anxiety and depression.  Responses are scored on a scale 
from 3 to 0, with a maximum of 21.  The HADS is divided into four ranges to 
identify caseness: normal (0-7), mild (8-10), moderate (11-15) and severe 
(16-21).  The HADS has demonstrated acceptable psychometric properties 
with cancer patients in a number of evaluation studies (Cronbach’s  α = .88; 
.82 for anxiety and .84 for depression subscale).30   
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2.4  Procedure 
 
Participants were a subset of those who participated in a larger insomnia 
study being conducted by researchers at the University of Glasgow Sleep 
Centre (UGSC).  The primary researcher/recruitment co-ordinator from the 
UGSC study, approached patients during routine clinic visits and provided 
information explaining the study, answered questions and then invited 
patients to participate.  Written informed consent was obtained from all 
patients who met study criteria and agreed to participate.  Data was collected 
during one clinic visit either face-to-face or remotely by post.  This meant 
study participants were not required to make an additional trip for research 
study purposes.  At the initial visit, eligibility criteria and demographic data 
were collected (Appendix 2.7).  Participants also completed instruments 
assessing physical activity, sleep, fatigue and mood.  To minimise participant 
burden, data was shared for measures that overlapped with the UGSC study 
(i.e. ISI, FSS and HADS).  Participation in current exercise activity was also 
examined by asking participants to report whether they engaged in light or 
moderate exercise (i.e., light exercise was defined as less than five days of 
walking of 30 minutes per day; moderate exercise was defined as 30 minutes 
of moderate activity, five or more days per week). 
 
For the actigraphy component, participants were asked to wear a wrist 
actiwatch for seven consecutive days.  The monitors were initialised before 
the recording period began and placed on the participant’s non-dominant 
wrist.  Participants also completed the IPAQ at three time-points over a 3-
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week period, Time 1 as test, Time 2 as re-test (plus actigraphy) and Time 3 
as re-test (no actigraphy).  It was therefore possible to test reliability of the 
IPAQ during the same 7-day period that the activity monitor was worn.  
Participants returned the actiwatch and questionnaires when the 
measurement period was complete.  Actigraphy data was uploaded from the 
monitors to a computer using Actiwatch Analysis software (version 5.03, 
Cambridge Neurotechnology Ltd, UK). 
 
2.5  Ethical Issues 
 
Informed consent was obtained from all participants by the primary 
researcher before initiation of any study measurements.  Ethical approval 
was granted from Greater Glasgow and Clyde NHS ethics committee 
(Appendix 2.8) and local Research and Development Management Office 
(Appendix 2.9).  
  
2.6  Statistical Power and Data Analysis 
 
Few studies have investigated physical activity and sleep in breast cancer 
patients, therefore, a study of related constructs was used to estimate the 
sample size needed to obtain power of 0.8, at an alpha of 0.05.  Humpel and 
Iverson,18 compared breast cancer and prostate cancer patients on 
measures of sleep and physical activity.  Results showed statistically 
significant differences between groups, in that a greater proportion of breast 
cancer patients reported sleep problems and lower levels of activity, 
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compared to prostate cancer patients.  A small to medium effect size was 
found (r = 0.30) for mean scores of activity and sleep.  For the present study, 
GPower analysis estimated that a sample size of 82 would be required to 
detect an effect of this magnitude and 26 participants would be required to 
detect a large effect size (r = 0.50).  Given that the current study used 
individuals of the same gender and cancer site (women with breast cancer), 
it was anticipated that a sample size of 26 would be sufficient to detect these 
associations if they existed.  Effect sizes for the current study were 
calculated by dividing the z-score by the square root of the total number of 
observations.31   
 
All analyses were performed using a Statistical Package for the Social 
Sciences (SPSS, version 18.0; SPSS Inc., Chicago, IL, USA).  A two-tailed 
hypothesis was used for all statistical analysis with an alpha level set at 0.05.  
The normality of the frequency distributions of all continuous variables were 
evaluated by the Kolmogorov-Smirnov statistic; only age was normally 
distributed.  As the assumptions for parametric tests were not met, 
Spearman’s correlations were used to assess relationships between 
variables.  Due to the skewed distribution of the IPAQ data, medians were 
presented to aid interpretation of the data.  Partial correlations were 
conducted between physical activity and sleep while controlling for the 
effects of fatigue and mood.  Secondary analyses included test-retest 
correlations to examine the reliability of IPAQ scores.  Correlations between 
IPAQ scores and actigraphy data were conducted to assess criterion validity.   
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RESULTS 
 
3.1  Participant characteristics 
 
Thirty-five breast cancer patients were invited to take part in the study.  A 
total of 31 took part resulting in a response rate of 88%.  However, data is 
only presented on 28 as three participants did not return questionnaires.  
Four participants declined due to work/family commitments (n=3) and health 
issues (n=1).  There were no significant differences between responders and 
non-responders on demographic variables and medical characteristics (see 
Appendix 2.10 for statistical analyses and significance levels).  Participants 
were recruited at six-months beyond diagnosis, following completion of 
breast cancer treatment.  The sample included women between the ages of 
43 and 75 (M = 58.3 years, SD = 8.8), 76% were married and 28% retired.  
Over half the sample had received a diagnosis of stage I breast cancer 
(54%) and almost a third stage II (29%).  The majority of women received a 
combination of surgery and radiotherapy/chemotherapy (92%); the remaining 
8% received surgery alone.  Fifty-five per cent engaged in light exercise and 
a minority reported no exercise activity (13%).  More than a third reported 
insomnia of moderate severity (40%) and exactly half reported symptoms of 
fatigue (50%).  The majority were within the normal range for anxiety and 
depression (68% and 82%, respectively).  Sixteen per cent discussed 
exercise with their oncologist/surgeon prior to treatment ending.  See 
Appendix 2.11 for percentage of individuals meeting diagnostic criteria.  
Table 1 provides demographic and medical information of the sample.   
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Table 1. Participants’ demographic and medical characteristics (N=28) 
 
Characteristic   Mean SD N (%)     
_____________________________________________________________ 
Age (years) mean (SD)  58.3  8.8 
Marital status 
Married      22 76 
Single      1 4 
Divorced      2 8 
Widowed      1 4 
Co-habiting     2 8 
Employment status 
Employed      16 57 
Not employed     1 4 
Retired      8 28 
Sick leave      3 11 
Breast cancer stage 
0       1 4 
1       17 54 
II       7 29 
III         3 13 
Treatment received   
Surgery alone     2 8 
Combination      26 92 
Current exercise activity  
None      3 13 
Light      16 55 
Moderate      9 32 
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3.2  Current levels of Activity  
 
Table 2 describes the weekly minutes of physical activity for the three IPAQ 
categories.  The median score for minutes of total physical activity was 585.  
The majority of the sample participated in walking (93%), with a median of 
420 min/wk.  The second most commonly reported activities were of 
moderate-intensity, with 68% participating in these activities, with a median 
of 95 min/wk.  Less common was participation in vigorous-intensity activities, 
with only 32% of women reporting these activities.  The median score for 
time spent sitting was 300 minutes, which was the equivalent of 
approximately 5 hours a day.  Participants who engaged in moderate-
intensity activities reported higher mean scores on measures of sleep (M = 
12.6), fatigue (M = 35.9), anxiety (M = 7.6) and depression (M = 5.6), 
compared to those who participated in high and low-intensity activities (see 
Appendix 2.12 for descriptive statistics of the ISI, FSS and HADS 
categorised by activity level).   
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Table 2. Minutes of weekly physical activity and sedentary timea 
reported by women following completion of breast cancer treatment 
based on the IPAQ (N=28) 
 
Activity type  % Median (IQR*)  Min, max 
_____________________________________________________________ 
Total physical activity   585 (1018)     0, 2550 
Walking     93  420 (690)     0, 1260  
Moderate     68      95 (536)     0, 1260 
Vigorous     32          0 (0)     0, 180  
Sitting    100  300 (5)   60, 780 
_____________________________________________________________ 
a Time spent sitting = total weekday daily minutes. 
* IQR: Interquartile Range. 
 
3.3  Physical Activity Categories 
 
Based on IPAQ scores, 50% of the sample were categorised as engaging in 
‘moderate’ levels of physical activity and 25% met criteria for ‘high’ and ‘low’ 
categories.  Since sample size was small and data were not normally 
distributed, a Kruskal-Wallis test was performed to examine differences in 
activity minutes between the three IPAQ categories (low, moderate, high).  
The analysis showed that the groups were significantly affected by the 
number of daily minutes engaged in physical activity (H (3) = 20.9, p < 0.001, 
see Figure 1).  Appendix 2.13 shows post hoc analysis and median values 
for the IPAQ categories.  In brief, a Jonckheere test revealed a significant 
trend in the data: as participants engaged in more vigorous-intensity 
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activities, the median minutes of activity also increased (J = 238.5, z = 5.020, 
r = .8).       
 
 
Figure 1. Boxplot of daily activity minutes for individuals engaging in 
different levels of physical activity per week  
 
 
3.4  Hypotheses 1, 2 and 3 - Physical activity and associations with 
sleep, fatigue and mood 
 
To examine associations between physical activity, sleep, fatigue and mood, 
Spearman’s correlations were carried out on total IPAQ scores (activity 
minutes and metabolic equivalent [MET] value), ISI, FSS scores and HADS 
anxiety and depression subscale scores. 
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IPAQ activity minutes 
 
The analysis showed that the predicted association between IPAQ activity 
minutes and sleep was statistically not significant (rs = .1, N = 28, p > 0.05).  
Similarly, IPAQ activity minutes were not significantly correlated with fatigue 
(rs = .1, N = 28, p > 0.05) or depression (rs = .2, N = 28, p > 0.05).  A 
significant positive correlation was found between IPAQ activity minutes and 
anxiety scores (rs = .4, N = 28, p < 0.05), indicating that higher levels of 
anxiety were moderately related to higher levels of activity (see Figure 2).  
  
 
 
Figure  2. Scatterplot showing a moderate positive correlation between 
IPAQ activity min/wk and HADS anxiety scores 
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The correlation coefficient of .4 suggests that 16% of the variation in activity 
levels may be accounted for by the variation in anxiety scores.  As there was 
no predicted association between physical activity and sleep, partial 
correlations controlling for the effects of fatigue and mood were not carried 
out.  Appendix 2.14 shows correlation coefficients and significance levels for 
IPAQ activity minutes, measures of sleep, fatigue and mood. 
 
IPAQ MET-minutes 
 
Calculated MET-mins from the IPAQ were not significantly correlated with 
sleep (rs = .1, N = 28, p > 0.05), fatigue (rs = .1, N = 28, p > 0.05), anxiety (rs = 
.3, N = 28, p > 0.05) or depression (rs = .2, N = 28, p > 0.05; see Appendix 
2.15 for correlation coefficients and significance levels).  These findings, 
therefore, do not support the hypotheses that lower levels of activity were 
related to poor sleep, worse fatigue and depression.  The IPAQ activity 
minutes data, however, provides partial support for the hypothesis that 
physical activity and anxiety were related, though not in the predicted 
direction.   
 
Table 3 shows the median values for the total MET-min/wk for each of the 
activities measured by the IPAQ.  As demonstrated by the means and 
medians, most variables were skewed.  Among walking, moderate and 
vigorous activities, the highest percentage of energy expenditure was related 
to walking, with a median value of 1386.  Using reported physical activity 
levels from the IPAQ, women were categorised according to national 
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physical activity guidelines.  Only 18% were sufficiently active to meet 
recommended guidelines.   
   
Table 3. IPAQ* MET-minsa of walking, moderate and vigorous-intensity 
activity and proportion of women meeting physical activity guidelinesb 
following breast cancer treatment (N=28) 
 
     % Median    Mean    Min,  
MET-min/wk  (SD)   max 
(IQR)     
_____________________________________________________________ 
Walking   1386 (2277)  1745.5 (1397.7) 0, 4158 
Moderate     380 (2145)  1102.1 (1442.0) 0, 5040 
Vigorous         0 (0)    158.6   (383.7) 0, 1440 
Meeting guidelines 18 7758          2415, 9198  
Not meeting 
guidelines                 82 2079                 0, 5652 
_____________________________________________________________ 
*IPAQ = International Physical Activity Questionnaire. 
a MET-mins = metabolic equivalents * min/wk. 
b Physical activity guidelines defined as 30 min of moderate activity, 5 or 
more days per week, or 20 min of vigorous activity on 3 or more days per 
week.  
 
3.5  Internal reliability of measures 
 
A reliability analysis was undertaken for each of the self-report measures.  All 
measures excluding the IPAQ demonstrated an acceptable level of internal 
consistency (Cronbach’s α = .53 for the IPAQ; ISI = .90; FSS = .94; .81 and 
.87 for the HADS anxiety and depression subscales respectively).  In view of 
the relatively low reliability of the IPAQ, further analysis showed that 
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removing item 3 from the scale (which represented vigorous-intensity 
scores), resulted in an increase in Cronbach’s alpha from .14 to .77 (see 
Appendix 2.16 for IPAQ, ISI, FSS and HADS mean and median scores). 
 
3.6  Hypothesis 4 – IPAQ reliability  
 
To evaluate the test-retest reliability of the IPAQ, Spearman’s correlations 
were carried out between T1 (test), T2 (retest) and T3 (retest) total IPAQ 
scores (i.e., activity minutes and MET-mins/week).  Table 4 shows no 
significant associations between test and retest results.  However, the 
moderately positive correlation between time spent sitting at T1 and T3 was 
marginally significant (rs = .6, n = 6, p = 0.07).  At T2 the magnitude of this 
relationship remained strong but did not reach significance (rs = .8, n = 6, p 
>0.05).  The latter coefficient may reflect fluctuations in test-retest reliability 
levels. The hypothesis that T1 IPAQ scores would correlate with T2 and T3 
IPAQ scores was, therefore, not supported by the results.  This effect, 
however, may have been due to limited power. 
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Table 4. Time 2 and Time 3 Spearman rank correlation coefficients for 
IPAQ activity minutes and MET-minutes per week (n=6) 
 
     
Variable   rs   Sig.  p 
_____________________________________________________________
T2 Activity minutes  -.1  NS*  0.803 
T3 Activity minutes   .3  NS  0.577  
 
T2 Walking MET-mins -.3  NS  0.612    
T3 Walking MET-mins  .4  NS  0.381 
 
T2 Moderate MET-mins  .4  NS  0.473 
T3 Moderate Met-mins  .7  NS  0.144 
 
T2 Vigorous MET-mins  .7  NS  0.125 
T3 Vigorous MET-mins  .6  NS  0.178 
 
T2 Sitting minutes   .6  NS  0.245 
T3 Sitting minutes   .8  NS  0.072 
_____________________________________________________________ 
*NS = not significant (p > 0.05, two-tailed). 
IPAQ = International Physical Activity Questionnaire; ISI = Insomnia Severity 
Scale; FSS = Fatigue Severity Scale; HADS = Hospital and Anxiety 
Depression Scale. 
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3.7  Hypothesis 5 – IPAQ construct validity  
 
IPAQ versus Actigraphy  
 
To examine the criterion validity of the IPAQ, self-reported energy 
expenditure (MET-mins week-1), was compared with objective activity counts 
(count-mins week-1).  Eight participants were initially invited to wear a wrist 
actiwatch, however, two declined due to health reasons.  Data is therefore 
presented on six participants.  Due to the small sample size, the strength of 
the relationship between IPAQ scores and actigraphy data was analysed 
using Spearman’s correlation.  The analysis showed a significant strong 
positive correlation between IPAQ MET-mins week-1 and actigraph count-
mins week-1 (rs = 0.8, n = 6, p < 0.001).  This suggests that subjective 
minutes of activity increased with objectively measured recording time (see 
Figure 3).  These findings support the hypothesis that the IPAQ and 
actigraph were measuring similar constructs and suggests the IPAQ may 
hold strong criterion validity. 
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Figure 3. Scatterplot showing a strong positive correlation between 
IPAQ MET-mins/week and Actigraphy count-mins/week 
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DISCUSSION  
 
4.1  Summary of results 
 
This study aimed to explore the relationships between physical activity, 
sleep, fatigue and mood in women who had completed treatment for breast 
cancer.  Secondary aims included examining the reliability and criterion 
validity of the IPAQ.  The results of the study showed that walking was the 
most common form of physical activity, with more than 90% preferring it as 
their primary mode of exercise.  The sample was relatively active with 50% of 
participants reporting moderate levels of physical activity.  Despite this, only 
18% met recommended physical activity guidelines.  Contrary to the study 
hypotheses, no significant associations were found between physical activity, 
sleep, fatigue or depression.  However, a moderately positive association 
was found between IPAQ activity minutes and anxiety, though not in the 
predicted direction.  Results of the IPAQ reliability data were poor with low 
correlation coefficients ranging from 0.1 to 0.3.  The criterion validity data 
showed a strong correlation between IPAQ scores and actigraphy data, 
suggesting high agreement between the two measures. 
 
4.2  Comparison with previous studies 
 
The findings that physical activity was not related to sleep, fatigue or 
depression, do not agree with previous research,2,18 which found that poor 
sleep, worse fatigue and depression were negatively associated with less 
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physical activity.  To explain these findings, the women in the study were 
functioning well, with only a minority meeting clinical cut-off for insomnia, 
fatigue and depression.  This restricted range of scores may have had a 
ceiling effect on the results, which may account for the inconsistency with 
previous studies.  Also, half the sample reported lower levels of fatigue when 
compared with levels in the general population and previous research.4   The 
non-significant correlation between depression and physical activity is, 
however, consistent with Mock et al.,32 who found no evidence that exercise 
was effective in reducing depression in breast cancer patients.  This 
discrepancy may have been due to relative high quality of life, as mean Total 
Depression scores in the current study were fairly low, suggesting that the 
sample was relatively free from distress.  Moreover, the literature suggests 
that the benefits of exercise towards reducing distress are stronger among 
individuals reporting higher levels of mood disturbance.33 
 
An important contribution of this study to the literature was the unexpected 
finding that increased anxiety significantly correlated with higher levels of 
activity.  While this finding conflicts with previous research of a negative 
relationship between anxiety and activity,33 it may provide support for Social 
Cognitive Theory in helping us understand some of the barriers to exercise 
participation.  It is possible, for example, that anxiety increased with more 
vigorous activities due to uncertainty about what was safe to do after breast 
cancer treatment.10   In addition, study participants confirmed a lack of 
medical advice, with the majority (84%) reporting that their 
oncologist/surgeon had not discussed exercise with them.  It is therefore 
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possible that a lack of confidence or self-efficacy led to increased anxiety as 
participants attempted to return to pre-diagnosis activity levels.  Evidence 
confirms this, as it is well established that the post-treatment period is a time 
of uncertainty with new challenges, higher stress levels and changed social 
influences.14   It is also possible that situational factors such as anticipatory 
anxiety associated with clinic attendance or psychosocial concerns relating 
to adjustment and coping impacted on anxiety levels.34  For example, 
participants were recruited 6-months post-diagnosis and a short time after 
treatment was complete.  The impact of psychosocial adjustment on physical 
activity is important to consider during this time, as the post-treatment period 
can be a time of instability and uncertainty about the future.  To capture the 
transition period’s acute nature, however, the study focused on a well-
defined time interval (diagnosis to 6-months post-diagnosis).  As a 
consequence, the study gives new perspectives for physical activity 
promotion by reporting the positive association with anxiety.  An examination 
of the influence of anxiety on activity could illuminate additional areas to 
target in breast cancer patients facing the prospect of returning to “normal” 
life after treatment. 
 
The test-retest reliability data for the IPAQ was low and although statistically 
non-significant is consistent with previous research.21   These results may be 
due to fluctuations in test-retest reliability levels or measurement error.20   
The high correlation coefficient of 0.8 between self-reported activity scores 
and objective actigraph data, suggests the IPAQ may hold strong criterion 
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validity.  However, the small sample size precludes a high criterion validity of 
the questionnaire and requires further validation with a larger sample.   
 
4.3  Study strengths, limitations and future research 
 
A particular strength of the study was the choice of activity monitor as an 
objective and valid criterion measure of physical activity.19   Objective activity 
measurements were performed during the same time period as the 
questionnaire, therefore, there is no reason to believe that respondents did 
not refer to the same day when answering the questionnaire.  However, the 
activity monitor and IPAQ captured only one week of activity.  It is, therefore, 
possible that activity during the week prior to completion of these measures, 
may be markedly different from a “normal” week and activity level may not 
have been fully captured.  The study is strengthened by its unique focus on 
sleep and physical activity among breast cancer patients after treatment. 
Only one study has examined this association among breast cancer 
patients18 and few studies have measured this following treatment.  
 
The current study is not without its limitations.  First, since the study was 
cross-sectional in design the findings cannot be regarded as providing a 
cause-effect relationship.  The findings should be confirmed by longitudinal 
analyses.  Nevertheless, the study documents the relationship between 
increased anxiety and activity for the first time in the breast cancer literature.  
Second, the study was limited by the use of self-reported activity, creating 
the possibility for recall bias and measurement error.  It is difficult to obtain a 
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good measure of low and moderate physical activity using self-administered 
questionnaires, because these activities are being accumulated throughout 
the day and, the number and diversity of these activities is enormous, 
resulting in poor recall.35   It has also been reported that people tend to 
overestimate time spent in high-intensity activities and underreport time 
spent in light and moderate-intensity activities, resulting in measurement 
error.35  However, the current study used the IPAQ short-version, which 
produces more accurate estimates than the IPAQ long-version, as it does not 
enquire about physical activity undertaken in specific domains (e.g. leisure 
time; domestic and gardening; work-related physical activity; transport-
related).  Another limitation of self-report, is that a single estimate of the 
energy cost of a specific activity is taken from a published compendium and 
applied to all individuals.24   This does not allow for inter-individual variation in 
energy expenditure for a given intensity or through variations in mechanical 
and metabolic efficiency.   
 
The study is also limited by the small sample size and potential loss of 
power.  However, consideration was given to effect size estimation and 
power analysis indicated that a sample of 26 would be sufficient to detect a 
large effect size.  Attempts were made to recruit as many participants as 
possible, however, numbers were limited due to timescales to complete the 
study.  It is also possible that the likelihood of Type I errors was increased as 
adjustments were not made to control for multiple comparisons. 
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Importantly, the study did not gather data on what activity was like prior to a 
breast cancer diagnosis.  Future studies should consider gathering baseline 
information on individual characteristics such as fitness level and history of 
physical activity, as these factors may influence participation in exercise.  
Lastly, participants in the study were primarily married, employed and most 
were diagnosed with early-stage tumours and, therefore, may not constitute 
a representative sample of the overall population of breast cancer patients.  
Additionally, it is very possible that those women who elected to participate in 
the study were coping better than breast cancer patients in general.  
Although the study collected demographic data on non-responders, the study 
did not collect activity data for potential participants who were not interested 
in participating in the study.  Therefore the possibility of a psychosocial self-
selection bias cannot be verified, but is plausible. 
 
4.4  Clinical implications and conclusion 
 
This is one of the first studies to find a relationship between high levels of 
anxiety and increased activity in patients following breast cancer treatment.  
The results are suggestive of a relationship but prospective data involving a 
larger sample size are required to adequately understand the direction and 
magnitude of the relationship.  The findings, however, have implications for 
improving health outcomes among breast cancer patients, as the majority of 
women did not meet national recommendations.  Future exercise 
programmes for breast cancer patients should include patient education and 
guidance by clinical staff.  While reliability of the IPAQ was low, there was 
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high agreement between the activity monitor and IPAQ, suggesting strong 
criterion validity.  Given the small sample size and possible selection effects, 
however, future studies should examine the reliability and validity of the 
IPAQ in a larger population of breast cancer patients.    
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ABSTRACT 
 
This reflective account describes my development working within a multi-
disciplinary team in a specialist adult mental health setting.  Particular 
reference is made to my developing competencies in relation to ethical and 
clinical practice as well as relational processes such as communicating 
psychological knowledge to others.  The account will draw on Rolfe’s 
framework for reflective practice (2001) and Schon’s model of reflection 
(1991). These models of reflection were chosen as they help to capture the 
fluid and dynamic nature of reflective practice across time.  The account will 
begin with a reflection of the impact of recent policy developments on the 
profession and wider National Health Service (NHS).  It will then provide a 
brief outline of a clinical case before moving on to describe my experiences, 
analysis of learning and action plan for future practice. 
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ABSTRACT 
 
This reflective account describes my development working within a multi-
disciplinary team in a specialist learning disability service.  Particular 
reference is made to my developing competencies in relation to research 
skills and service evaluation, as well as staff training and management.  The 
account will draw on Gibbs’ framework for reflective practice and Schon’s 
model of reflection.  These models of reflection were chosen because they 
help to capture the meaning of experiences and allow conceptual 
perspectives to change.  The account will begin with a reflection of the 
impact of recent policy developments on the identification and management 
of gender-based violence within learning disability services.  It will then 
provide a description of events before moving on to describe the stages of 
self-awareness, evaluation and analysis of learning, synthesis and action 
plan for my future practice. 
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APPENDIX 1.1 
 
 
CLINICAL TRIALS ASSESSMENT MEASURE (CTAM) 
 
 
Sample – two questions: maximum score = 10 
 
Q1 Is the sample a convenience sample (score 2) or a geographic cohort 
(score 5), highly selective sample, e.g. volunteers (score 0); convenience 
sample, e.g. clinic attendees, referred patients or geographic cohort – all 
patients eligible in a particular area 
__ 
Q2 Is the sample size greater than 27 participants in each treatment group 
(score 5) or based on described and adequate power calculations (score 
5) 
__ 
  
Allocation – three questions: maximum score = 16 
 
Q3 Is there true random allocation or minimisation allocation to treatment 
groups (if yes score 10) 
__ 
Q4 Is the process of randomisation described (score 3) __ 
Q5 Is the process of randomisation carried out independently from the trial 
research team (score 3) 
__ 
 
Assessment (for the main outcome) – five questions: maximum score = 32 
 
Q6 Are the assessments carried out by independent assessors and not 
therapists (score 10) 
__ 
Q7 Are standardised assessments used to measure symptoms in a standard 
way (score 6), idiosyncratic assessments of symptoms (score 3) 
__ 
Q8 Are assessments carried out blind (masked) to treatment group 
allocation (score 10) 
__ 
Q9 Are the methods of rater blinding adequately described (score 3) __ 
Q10 Is rater blinding verified (score 3) __ 
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Control groups – one question: maximum score = 16 
 
Q11 TAU is a control group (score 6) and/or a control group that controls for 
non-specific effects or other established or credible treatment (score 10) 
__ 
 
Analysis – two questions: maximum score = 15 
 
Q12 The analysis is appropriate to the design and the type of outcome 
measure (score 5) 
__ 
Q13 The analysis includes all those participants as randomised (sometimes 
referred to as an intention to treat analysis) (score 6) and an adequate 
investigation and handling of drop outs from assessment if the attrition 
rate exceeds 15% (score 4) 
__ 
 
Active treatment – two questions: maximum score = 11 
 
Q14 Was the treatment adequately described (score 3) and was a treatment 
protocol or manual used (score 3) 
__ 
Q15 Was adherence to the treatment protocol or treatment quality assessed 
(score 5) 
__ 
 
 Where the criterion is not reached for any question score = 0 
 Total score: maximum score = 100 
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APPENDIX 1.2 
 
EFFECT SIZE CALCULATION  
 
Effect sizes were calculated by authors in five studies (Vallance et al., 2007; 
Daley et al., 2007; Fillion et al., 2008; Milne et al., 2008; Rogers et al., 2009) 
using Cohen’s d (1992).  Cohen’s d was used as the preferred procedure for 
calculating effect sizes, namely the difference between two group outcomes 
divided by the population standard deviation.  This is represented in the 
following formula: 
 
 
 
Effect sizes were not computed for two studies due to insufficient information 
(Payne et al., 2008) and null findings (Cadmus et al., 2009).  A meta-analysis 
was not felt to be appropriate due to the small number of studies, differences 
in methodological design and measurement of different psychosocial 
domains.  Related to this, the review did not address the ‘file drawer’ problem 
i.e. bias attributable to the tendency for studies with large effect sizes to be 
published.  Statistical methods have been developed for dealing with this 
issue within meta-analyses, however, this only becomes an issue when 
many of the studies remain unpublished.  This is unlikely to be the case 
within the emerging evidence base described in the review. 
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APPENDIX 1.3 Characteristics of excluded studies  
 
Badger 2007  Not a randomised controlled trial 
_________________________________________________________________________ 
Basen-Engquist 2006 Participants not predominantly Stage I-III (included Stage IV breast 
cancer) 
_________________________________________________________________________ 
Blacklock 2010  Not a randomised controlled trial 
_________________________________________________________________________ 
Courneya 2007a Participants receiving treatment 
_________________________________________________________________________ 
Courneya 2007b 6-month follow-up study of Courneya 2007a 
_________________________________________________________________________ 
Courneya 2008  Qualitative data 
_________________________________________________________________________ 
Courneya 2009  Participants receiving treatment 
_________________________________________________________________________ 
Hwang 2008  Participants receiving treatment 
_________________________________________________________________________ 
Irwin 2008  Outcome measures not relevant to this review (biological markers) 
_________________________________________________________________________ 
Jones 2010  No published data, design paper 
_________________________________________________________________________ 
Latka 2009  Outcomes not relevant to this review (adherence study) 
_________________________________________________________________________ 
Mayer 2010  Outcomes not relevant to this review (pharmacological intervention) 
_________________________________________________________________________ 
McClure 2010 Participants not predominantly Stage I-III (included breast-cancer 
related lymphoedema) 
_________________________________________________________________________ 
Mutrie 2007  Participants receiving treatment 
_________________________________________________________________________ 
Ohira 2006  Time since treatment <12 months  
_________________________________________________________________________ 
Pinto 2009  Outcomes not relevant to this review (adherence study) 
_________________________________________________________________________ 
Yang 2010  Participants receiving treatment 
_________________________________________________________________________ 
Wang 2011   Not a randomised controlled trial 
_________________________________________________________________________ 
Wu 2008   Participants receiving treatment  
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APPENDIX 1.4     Quality Assessment Ratings for Included Studies 
 
 
 
Study 
 
1 
 
2   
 
Sample 
Score 
 
3 
 
4 
 
5 
 
Allocation 
Score 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Assessment 
Score 
 
11 
 
Control 
Group 
Score 
 
12 
 
13 
 
Analysis 
Score 
 
 
14 
 
15 
 
Active 
Treatment 
Score 
 
Total 
CTAM 
Score 
Daley  
et al 2007 
 
2 
 
5 
 
7/10 
 
 
10 
 
3 
 
3 
 
16/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
16 
 
16/16 
 
5 
 
10 
 
15/15 
 
6 
 
5 
 
11/11 
 
71/100 
Vallance et al 
2007 
 
 
5 
 
5 
 
10/10 
 
10 
 
3 
 
0 
 
13/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
16 
 
16/16 
 
5 
 
10 
 
15/15 
 
3 
 
5 
 
8/11 
 
68/100 
Fillion  
et al 2008 
 
 
2 
 
5 
 
7/10 
 
10 
 
3 
 
0 
 
13/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
6 
 
6/16 
 
5 
 
10 
 
15/15 
 
6 
 
5 
 
11/11 
 
58/100 
Milne 
 et al 2008 
 
 
2 
 
5 
 
7/10 
 
10 
 
3 
 
0 
 
13/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
6 
 
6/16 
 
5 
 
10 
 
15/15 
 
6 
 
5 
 
11/11 
 
58/100 
Rogers et al 
2009 
 
 
5 
 
0 
 
5/10 
 
10 
 
0 
 
3 
 
13/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
6 
 
6/16 
 
5 
 
10 
 
15/15 
 
6 
 
5 
 
11/11 
 
56/100 
Cadmus et al 
2009 
 
 
5 
 
5 
 
10/10 
 
10 
 
3 
 
0 
 
13/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
6 
 
6/16 
 
5 
 
10 
 
15/15 
 
0 
 
5 
 
5/11 
 
55/100 
Payne et al 
2008 
 
 
2 
 
0 
 
2/10 
 
0 
 
0 
 
0 
 
0/16 
 
0 
 
6 
 
0 
 
0 
 
0 
 
6/32 
 
6 
 
6/16 
 
5 
 
0 
 
5/15 
 
0 
 
0 
 
0/11 
 
19/100 
 
Key: 
Item 1. Is the sample a convenience sample (score 2) or a geographic cohort (score 5), highly selective sample, e.g. volunteers? (score 0) 
Item 2. Is the sample size greater than 27 participants in each treatment group (score 5) or based on described and adequate power calculations? 
(score 5) 
Item 3. Is there true random allocation or minimisation allocation to treatment groups? (score 10) 
Item 4. Is the process of randomisation described? (score 3) 
Item 5. Is the process of randomisation carried out independently from the trial research team? (score 3) 
Item 6. Are the assessments carried out by independent assessors and not therapists? (score 10) 
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Item 7. Are standardised assessments used to measure symptoms in a standard way (score 6), idiosyncratic assessments of symptoms? (score 3) 
Item 8. Are assessments carried out blind (masked) to treatment group allocation? (score 10) 
Item 9.  Are the methods of rater blinding adequately described? (score 3) 
Item10. Is rater blinding verified? (score 3) 
Item11.TAU is a control group (score 6) and/or a control group that controls for non-specific effects or other established or credible treatment? 
(score 10) 
Item12.The analysis is appropriate to the design and the type of outcome measure? (score 5) 
Item13.The analysis includes all those participants as randomised (sometimes referred to as an intention to treat analysis) (score 6) and an 
adequate investigation and handling of drop outs from assessment if the attrition rate exceeds 15%? (score 4) 
Item14. Was the treatment adequately described (score 3) and was a treatment protocol or manual used? (score 3)  
Item15.Was adherence to the treatment protocol or treatment quality assessed? (score 5)  
 
Note: Where the criterion is not reached for any question score = 0 
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APPENDIX 1.5 
GUIDELINES FOR SUBMISSION TO PSYCHO-ONCOLOGY 
 
Manuscript Preparation  
Address manuscripts to the Editor: Journal of Psychosocial Oncology receives 
all manuscript submissions electronically via their Scholar One Manuscripts website 
located at: http://mc.manuscriptcentral.com/WJPO. Scholar One Manuscripts allows 
for rapid submission of original and revised manuscripts, as well as facilitating the 
review process and internal communication between authors, editors and reviewers 
via a web-based platform. For Scholar One Manuscripts technical support, you may 
contact them by e-mail or phone support via 
http://scholarone.com/services/support/. If you have any other requests please 
contact the journal at mailforkrish@gmail.com. 
Authors must complete a Copyright Transfer Form Each manuscript must be 
accompanied by a statement that it has not been published elsewhere and that it 
has not been submitted simultaneously for publication elsewhere. Authors are 
responsible for obtaining permission to reproduce copyrighted material from other 
sources and are required to sign an agreement for the transfer of copyright to the 
publisher. All accepted manuscripts, artwork, and photographs become the property 
of the publisher. 
All parts of the manuscript should be typewritten, double-spaced, with margins of at 
least one inch on all sides. Number manuscript pages consecutively throughout the 
paper. Authors should also supply a shortened version of the title suitable for the 
running head, not exceeding 50 character spaces. Each article should be 
summarized in an abstract of not more than 100 words. Avoid abbreviations, 
diagrams, and reference to the text in the abstract. 
References. References, citations, and general style of manuscripts should be 
prepared in accordance with the APA Publication Manual, 4th ed. Cite in the text by 
author and date (Smith, 1983) and include an alphabetical list at the end of the 
article.  
Illustrations. Illustrations submitted (line drawing, halftones, photos, 
photomicrographs, etc.) should be clean originals or digital files. 
Digital files are recommended for highest quality reproduction and should follow 
these guidelines: 
300 dpi or higher  
Sized to fit on journal page  
EPS, TIFF, or PSD format only  
Submitted as separate files, not embedded in text files  
Color Illustrations. Color illustrations will be considered for publication; however, 
the author will be required to bear the full cost involved in color art reproduction. 
Color art can be purchased for online only reproduction or for print+online 
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reproduction. Color reprints can only be ordered if print+online reproduction costs 
are paid. Rates for color art reproduction are: Online Only Reproduction: $225 for 
the first page of color; $100 per page for the next three pages of color. A maximum 
charge of $525 applies. Print + Online Reproduction: $900 for the first page of color; 
$450 per page for the next three pages of color. A custom quote will be provided for 
articles with more than 4 pages of color. 
Tables and Figures. Tables and figures (illustrations) should not be embedded in 
the text, but should be included as separate sheets or files. A short descriptive title 
should appear above each table with a clear legend and any footnotes suitably 
identified below. All units must be included. Figures should be completely labelled, 
taking into account necessary size reduction. Captions should be typed, double-
spaced, on a separate sheet. 
Proofs. Page proofs are sent to the designated author using Taylor & Francis' 
Central Article Tracking System (CATS). They must be carefully checked and 
returned within 48 hours of receipt.  
Reprints and Issues. Reprints of individual articles; are available for order at the 
time authors review page proofs. A discount on reprints is available to authors who 
order before print publication. Each corresponding author will receive 3 complete 
issues in which the article publishes and a complimentary PDF. This file is for 
personal use only and may not be copied and disseminated in any form without 
prior written permission from Taylor and Francis Group, LLC. 
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APPENDIX 2.1 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE (7-day recall) 
 
 
We are interested in finding out about the kinds of physical activities that people 
do as part of their everyday lives following a diagnosis of breast cancer. The 
questions are about the time you spent being physically active in the last 7 days. 
They include questions about activities you do at work, as part of your house 
and garden work, to get from place to place, and in your spare time for 
recreation, exercise or sport. 
 
Please answer each question even if you do not consider yourself to be 
an active person. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling? 
 
Think about only those physical activities that you did for at least 10 
minutes at a time. 
 
________ days per week 
 
How much time did you usually spend doing vigorous physical activities 
on one of those days? 
 
_________ hours per day 
 
_________ minutes per day 
 
 
 No vigorous physical activities 
 
 
 
2. Again, think only about those physical activities that you did for at least 
10 minutes at a time. During the last 7 days, on how many days did you 
do moderate physical activities like carrying light loads, bicycling at a 
regular pace, or doubles tennis? Do not include walking. 
 
________ days per week  
 
 
 
In answering the following questions,  
 Vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder than normal. 
 Moderate physical activities refer to activities that take moderate physical 
effort and make you breathe somewhat harder than normal. 
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How much time did you usually spend doing moderate physical activities 
on one of those days? 
 
________ hours per day 
 
________ minutes per day 
 
 
 No moderate physical activities 
 
 
 
3. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time? This includes walking at work and at home, walking to 
travel from place to place and any other walking that you did solely for 
recreation, sport, exercise or leisure. 
 
________ days per week  
 
How much time did you usually spend walking on one of those days? 
 
________ hours per day 
 
________ minutes per day 
 
 
 No walking 
 
 
The last question is about the time you spent sitting on weekdays during the 
last 7 days.  Include time spent at work, at home and during leisure time.  This 
may include time spent sitting at a desk, visiting friends, reading or sitting or 
lying down to watch television. 
 
 
4. During the last 7 days, how much time in total did you usually spend 
sitting on a week day? 
 
_______ hours per day  
 
_______ minutes per day 
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APPENDIX 2.2 
 
IPAQ SCORING PROTOCOL 
 
According to the published IPAQ scoring protocol, the cut-off point values for 
the three levels of physical activity are: Category 1 [Low], which is the lowest 
level of physical activity and includes individuals who do not meet criteria for 
Categories 2 or 3, Category 2 [Moderate], includes individuals engaging in 
three or more days of vigorous-intensity activity of at least 20 minutes per 
day OR five or more days of moderate-intensity activity and/or walking of at 
least 30 minutes per day OR five or more days of any combination of 
walking, moderate-intensity or vigorous intensity activities achieving a 
minimum Total physical activity of at least 600 MET-minutes/week and, 
Category 3 [High], includes those individuals engaging in vigorous-intensity 
activity on at least three days achieving a minimum Total physical activity of 
at least 1500 MET-minutes per week OR seven or more days of any 
combination of walking, moderate-intensity or vigorous-intensity activities 
achieving a minimum Total physical activity of at least 3000 MET-minutes 
per week.   
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APPENDIX 2.3 
 
EXAMPLE OF A WRIST ACTIWATCH 
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APPENDIX 2.4 
INSOMNIA SEVERITY INDEX 
 
Please respond to these questions, even if you do not have a sleep problem 
currently. 
1. Please rate the current (i.e., last month) severity of your insomnia 
problem(s). 
None Mild Moderate Severe   Very severe 
a. Difficulty falling asleep:      0      1         2           3          4 
b. Difficulty staying asleep:      0      1         2           3          4 
c. Problem waking up too early:    0      1         2           3          4 
 
2. How satisfied/dissatisfied are you with your current sleep pattern? 
Very satisfied  Satisfied  Neutral  Dissatisfied  Very dissatisfied 
       0         1       2         3   4  
 
3. To what extent do you consider your sleep problem to interfere with your 
daily functioning (e.g. daytime fatigue, ability to function at work/daily chores, 
concentration, memory, mood, etc)? 
Not at all  
interfering        A little Somewhat   Much   Very much interfering 
       0        1                    2                 3                           4 
 
4. How noticeable to others do you think your sleeping problem is in terms of 
impairing the quality of your life?       
 
Not at all  
interfering        A little Somewhat   Much   Very much interfering 
       0        1                    2                 3                           4 
 
5. How worried/distressed are you about your current sleep problem?  
  
Not at all  
interfering        A little Somewhat   Much   Very much interfering 
       0        1                    2                 3                           4 
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APPENDIX 2.5 
FATIGUE SEVERITY SCALE 
 
Read each statement and circle a number from 1 to 7, depending on how 
appropriate you feel the statement applies to you over the preceding week. A 
low value indicates that the statement is not very appropriate whereas a high 
value indicates agreement.  
FSS Questionnaire 
During the past week, I have found that: Score 
    1. My motivation is lower when I am fatigued. 1 2 3 4 5 6 7 
    2. Exercise brings on my fatigue. 1 2 3 4 5 6 7 
    3. I am easily fatigued. 1 2 3 4 5 6 7 
    4. Fatigue interferes with my physical functioning. 1 2 3 4 5 6 7 
    5. Fatigue causes frequent problems for me. 1 2 3 4 5 6 7 
    6. My fatigue prevents sustained physical functioning. 1 2 3 4 5 6 7 
    7. Fatigue interferes with carrying out certain duties and       
responsibilities. 
1 2 3 4 5 6 7 
    8. Fatigue is among my three most disabling symptoms. 1 2 3 4 5 6 7 
    9. Fatigue interferes with my work, family, or social life. 1 2 3 4 5 6 7 
 
   
 
 
105 
 
APPENDIX 2.6     HOSPITAL AND 
ANXIETY  DEPRESSION SCALE 
 
 
 
 
1.  I feel tense or “wound up” 
Most of the time . . . . . . . . . . . . . .  
A lot of the time . . . . . . . . . . . . . .  
Time to Time, Occasionally . . . . .  
Not at all . . . . . . . . . . . . . . . . . . .  
 
2.  I still enjoy the things I used to enjoy 
Definitely as much. . . . . . . . . . . . .   
Not quite as much. . . . . . . . . . . . .  
Only a little. . . . . . . . . . . . . . . . . .  
Hardly at all . . . . . . . . . . . . . . . . .  
 
3.  I get a sort of frightened feeling as if 
     something awful is about to happen 
Very definitely and quite badly . . .  
Yes, but not too badly  . . . . . . . . .   
Time to Time, Occasionally  . . . . .  
Not at all  . . . . . . . . . . . . . . . . . . .  
 
4.  I can laugh and see the funny side of 
     things 
As much as I always could  . . . . . .  
Not quite so much now . . . . . . . . .  
Definitely not so much now  . . . . .   
Not at all  . . . . . . . . . . . . . . . . . . .  
 
 
 
 
 
 
 
 
 
 
5.  Worrying thoughts go through my mind 
A great deal of the time  . . . . . . . .  
A lot of the time . . . . . . . . . . . . . .  
From time to time but not too often  
Only occasionally . . . . . . . . . . . . .  
 
6.  I feel cheerful 
Not at all  . . . . . . . . . . . . . . . . . . .   
Not often . . . . . . . . . . . . . . . . . . .  
Sometimes . . . . . . . . . . . . . . . . . .  
Most of the time  . . . . . . . . . . . . .   
 
7.  I can sit at ease and feel relaxed 
Definitely . . . . . . . . . . . . . . . . . . .  
Usually . . . . . . . . . . . . . . . . . . . . .   
Not Often . . . . . . . . . . . . . . . . . . .  
Not at all  . . . . . . . . . . . . . . . . . . .  
 
8.  I feel as if I am slowed down 
Nearly all the time . . . . . . . . . . . . . .   
Very often  . . . . . . . . . . . . . . . . . . .  
Sometimes  . . . . . . . . . . . . . . . . . . .  
Not at all   . . . . . . . . . . . . . . . . . . . .  
 
The next part of the questionnaire asks about how you have been feeling.  Please 
read each item below and circle one number opposite the reply which comes closest 
to how you have been feeling in the past week.  Don’t take too long over your replies, 
your immediate reaction to each item will probably be more accurate than a long 
thought-out response. 
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9.  I get a sort of frightened feeling like      
     butterflies in the stomach 
Not at all  . . . . . . . . . . . . . . . . . . . .  
Occasionally . . . . . . . . . . . . . . . . . .  
Quite often . . . . . . . . . . . . . . . . . . .  
Very often  . . . . . . . . . . . . . . . . . . .  
 
10.  I have lost interest in my appearance 
Definitely   . . . . . . . . . . . . . . . . . . .  
I don’t take so much care as I should  
I may not take quite as much care . .   
I take just as much care as ever . . . .  
 
11.  I feel restless as if I have to be on the 
       move 
Very much indeed . . . . . . . . . . . . .   
Quite a lot. . . . . . . . . . . . . . . . . . .  
Not very much. . . . . . . . . . . . . . . .   
Not at all   . . . . . . . . . . . . . . . . . . .  
 
12.  I look forward with enjoyment to 
       things 
As much as ever I did . . . . . . . . . .   
Rather less than I used to . . . . . . .  
Definitely less than I used to . . . . .  
Hardly at all  . . . . . . . . . . . . . . . . .   
 
 
13.  I get sudden feeling of panic 
Very often indeed . . . . . . . . . . . . .   
Quite often . . . . . . . . . . . . . . . . . .  
Not very often  . . . . . . . . . . . . . . .   
Not at all  . . . . . . . . . . . . . . . . . . .  
 
 
14.  I can enjoy a good book or radio or 
      TV programme 
Often   . . . . . . . . . . . . . . . . . . . . .  
Sometimes . . . . . . . . . . . . . . . . . .  
Not Often. . . . . . . . . . . . . . . . . . .  
Very seldom . . . . . . . . . . . . . . . . .   
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APPENDIX 2.7 
ELIGIBILITY INTERVIEW 
                         
 
Investigating Everyday Physical Activity with  
Sleep, Fatigue and Mood in Patients with Breast Cancer. 
 
 
ID                               Date:                                  (for office purposes) 
 
Please answer all of the questions.  All information will be treated in the 
strictest confidence. 
Gender:     Male     Female 
Age: __________________  
Marital status:  married     single     divorced     widowed    
Occupation: _____________________________________ 
Retired:   Yes     No   
Which type of cancer have you been diagnosed 
with?___________________________________________________________ 
Have you started anti-cancer treatment?  Yes        No 
What treatment? (Chemotherapy; Radiotherapy; Hormone treatment; 
Surgery) 
_________________________________________________________ 
Do you have any further cancer treatment planned? (please give details) 
________________________________________________________________ 
________________________________________________________________ 
Have any of the clinicians talked to you about physical activity levels 
during/after treatment? 
Yes No 
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We are interested in how you have been sleeping. Firstly, please answer 
the following questions in relation to your sleep in the month BEFORE 
you were diagnosed with breast cancer. 
1. In the month prior to your diagnosis, did you have problems with any of the 
following: 
 Difficulty falling asleep                           Y               N 
 Difficulty staying asleep                         Y               N 
 Problem waking too early                       Y               N 
 
If you answered yes to one or more of the above, please answer questions 2 to 
7 If not, please go to question 8 
2. How many days a week were you bothered with these sleeping problems? 
 
________________________________________________________________ 
3. When did these sleeping problems start? _________________ 
4. Did this sleep problem affect how you felt and functioned during the day? 
(e.g. fatigue, sleepiness, concentration, memory, mood, motivation, irritable, 
work/social functioning etc.)   
________________________________________________________________
________________________________________________________________ 
5. How worried or distressed were you about these sleeping problems?  
________________________________________________________________ 
6. Were you satisfied with your 
sleep?____________________________________ 
7. Were you taking any prescribed OR over-the-counter medicines for your sleep 
during this period?     Yes           No 
What 
medication?_____________________________________________________ 
How many nights a week were you taking this?___________________________ 
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The next set of questions will ask about your sleeping habits in the last 
few weeks, FOLLOWING your breast cancer diagnosis 
8. What time do you normally go to 
bed?_________________________________ 
9. What time do you normally get up? 
___________________________________ 
10.  How much sleep do you normally get each night (hours/minutes)? 
________________________________________________________________ 
11. How long does it normally take you to fall asleep? (minutes) 
________________________________________________________________ 
12. Do you tend to take naps during the day?   Yes             No 
If yes, on average, how many days per week do you take naps? 
__________________________________________ 
Roughly how long do you tend to nap for? 
____________________________________________ 
13. Are you currently satisfied with your sleep?   
________________________________________________________________ 
14. Are you currently taking any prescribed OR over- the-counter medicines to 
help with your sleep?  
            Yes             No 
If yes, please give medicine name and dose 
_____________________________________________________________ 
How many nights per week are you taking them? 
_________________________ 
15. Have you ever attended therapy for insomnia or any other sleep problem? 
________________________________________________________________ 
16. Do you work shifts or night shifts? 
________________________________________________________________ 
17. Do you CURRENTLY have any problems sleeping?     Yes                  No 
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If you ARE currently having problems with your sleep, the next few 
questions will ask you a few more detailed questions to establish the 
nature of your sleep problem. If you do not currently have any problems 
with your sleep, please go to question 42. 
18. Have you always been a poor sleeper?  Yes             No 
19.  How long have you had problems with your sleep 
(months)?________________ 
20.  On average, how many nights per week do you have difficulties sleeping? 
________________________________________________________________ 
21. On average, how many nights per week do you have difficulty falling asleep?  
________________________________________________________________ 
22. On average, how many nights per week do you have difficulty staying 
asleep? 
________________________________________________________________ 
23. If you can’t stay asleep, how long are you usually awake during the night? 
________________________________________________________________ 
24.  Does your sleep problem affect how you feel and function during the day? 
(e.g. fatigue, sleepiness, concentration, memory, mood, motivation, irritable, 
work/social functioning etc.)    
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
25.  Do you know the main cause(s) of your sleeping problem?  If so, please 
explain.  For example, did this occur at a time of stress or life changes? 
________________________________________________________________ 
________________________________________________________________ 
26.   Has your sleep problem been constant over the years or does it come in 
spells?  
________________________________________________________________ 
27.  Does pain or physical discomfort interrupt your sleep at night?  
          Never       Sometimes       Usually    Always 
28. Does taking pain medication help this? 
 
          Never       Sometimes       Usually    Always 
29. Do you think that pain is the main cause of your sleeping problem (if yes, 
please specify the nature of the pain)?   
________________________________________________________________
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Do you snore during your sleep?  
                  Never          Sometimes       Usually    Always 
30.  If you do, how do you know?  For example, has your partner been awoken? 
________________________________________________________________ 
________________________________________________________________ 
31. Do you hold your breath, have breathing pauses or stop breathing in your 
sleep? 
 
                  Never          Sometimes       Usually    Always 
32.  If you do, how do you know?  For example, has your partner noticed this? 
________________________________________________________________ 
________________________________________________________________ 
33. Do you think breathing difficulties may be the main cause of your sleeping 
problem? 
________________________________________________________________ 
35. Why do you think this is the case? 
________________________________________________________________ 
36.  Do you experience repeated, uncontrollable leg jerks or leg twitches during 
your sleep? 
                 Never          Sometimes       Usually    Always 
37.   Do you think such uncontrolled limb movements may be the main cause of 
your sleeping problem? 
 
________________________________________________________________ 
38.  Do you experience restless or “crawling” feelings in your legs at night which 
go away if you move your legs?            
       Never          Sometimes       Usually    Always 
39.  Do you think such restless legs may be the main cause of your sleeping 
problem? 
________________________________________________________________ 
________________________________________________________________ 
40.  Do you fall asleep unintentionally or have to fight to stay awake during the 
day? 
       Never          Sometimes       Usually    Always 
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41. How likely are you to doze off or fall asleep in the following situations, in 
contrast to feeling just tired?  This refers to your usual way of life in recent 
times.  Even if you have not done some of these things recently try to work out 
how they would have affected you.  Use the following scale to choose the most 
appropriate number for each situation. 
 0 = would never doze 
 1 = slight chance of dozing 
 2 = moderate chance of dozing 
 3 = high chance of dozing 
Situation        Chance of dozing 
Sitting and reading               ............................. 
Watching TV                ............................. 
Sitting, inactive in a public place                       
(e.g. a theatre or a meeting)                       ............................. 
As a passenger in a car for an hour  
without a break                        ............................. 
Lying down in the afternoon to rest  
when circumstances permit                                 ............................. 
Sitting and talking to someone                       ............................. 
Sitting quietly after lunch without alcohol   ............................. 
In a car, while stopped for a few minutes  
in the traffic                                              ............................. 
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The next set of questions will ask about how you have been feeling 
emotionally in the last few weeks 
42.  Have you felt particularly worried or anxious about things recently?  If so, 
when did this start?  What are you worrying about? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
43. Have you felt particularly ‘down’ or ‘sad’ or ‘empty’ about things in the past 
two weeks?   
  Never          Sometimes       Usually    Always 
44.  Does your doctor know about this? 
________________________________________________________________ 
45.  Are these low feelings a change from what is normal for you?   
________________________________________________________________ 
46. When did these low feelings start? 
________________________________________________________________ 
47.  In the past two weeks :  
Have you lost pleasure in your usual activities?    ________               
  
Has your appetite changed?      ________  
Have you lost or gained weight?      ________                 
Have you lacked energy?                              ________  
Have you felt agitated?                           ________ 
Have you felt slowed down?                                                 ________ 
Have you thought about harming yourself?              ______ 
Have you felt excessively guilty or worthless?                         ________  
Has your concentration been poor?                                       ________ 
  
48.  Are you currently being treated for depression? If yes, please give details. 
________________________________________________________________ 
49. Have you ever been diagnosed with any psychiatric disorder?  
Yes      No 
If yes, are you currently receiving any treatment for this? Please give details 
________________________________________________________________ 
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The next questions relate to your lifestyle and aspects of your general 
health  
50.  Do you smoke tobacco?  If yes, how many cigarette’s/cigars per day? 
________________________________________________________________ 
51. Do you drink alcohol?    Yes       No 
If yes, roughly how many units of alcohol do you drink per week?  
(Remember: One standard (175ml) glass of wine = 2 units 
One pint of standard lager = 2.3 units 
Spirit & mixer = 1 unit) 
_______________________________________________________________ 
52. Do you take any non prescription drugs? If yes please give details 
________________________________________________________________ 
________________________________________________________________ 
53. Do you exercise? If yes, how often and what types of activity? 
Number of times per week: ________________ 
Average time per session: _________________ 
Types of activity (e.g. walking, cycling, swimming, jogging, aerobics): 
________________________________________________________________ 
54. Has your oncologist/surgeon discussed physical activity with you? 
54.  Do you have any other health problems? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
55. What medicines do you take for your physical health?  
________________________________________________________________ 
___________________________________________________________________ 
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APPENDIX 2.10 
 
Statistical Analysis of Demographic Variables and Medical 
Characteristics (N=35) 
 
 
Variable Test Value  M (SD) df Sig. p 
_____________________________________________________________ 
 
Age  t 0.559  57.8 (8.4) 33 NS* .580 
Marital status χ2** 7.318    4 NS* .093 
Employment χ2** 4.571    4 NS* .406  
Tumour stage χ2** 1.872    3 NS* .588 
Treatment χ2** 0.530    1 NS* .635 
_____________________________________________________________ 
 
*NS = not significant (p > 0.05, two-tailed). 
** The analysis showed that 2 cells had expected counts less than 5, therefore 
Fisher’s Exact Test was selected for Pearson’s Chi-square. 
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APPENDIX 2.11 
 
Percentage of participants meeting diagnostic criteria for insomnia, 
fatigue, anxiety and depression (N=28) 
 
   
Variable     % 
_____________________________________________________________ 
 
ISI  
No insomnia    32 
Subthreshold insomnia  40 
Clinical insomnia   21 
Severe insomnia    7 
FSS 
Fatigue present   50 
No fatigue    50 
HADS anxiety subscale 
Normal    68 
Mild     21 
Moderate    11 
Severe     0 
HADS depression subscale  
Normal    82 
Mild     11 
Moderate     0 
Severe     4 
_____________________________________________________________ 
 
ISI = Insomnia Severity Scale; FSS = Fatigue Severity Scale; HADS = 
Hospital and Anxiety Depression Scale. 
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APPENDIX 2.12 
 
Descriptive Statistics for Outcome Variables categorised by Physical 
Activity level* (N=28) 
 
 
Outcome variable   Mean (SD) Min, Max 
 
 
ISI 
Low PA      9.4 (5.7)   2, 20     
Moderate PA   12.6 (6.8)   3, 28  
High PA      9.7 (7.1)   2, 22 
FSS 
Low PA    31.7 (15.5)   9, 57 
Moderate PA    35.9 (13.5) 14, 63 
High PA    32.3 (18.4) 11, 55 
HADS Anxiety subscale 
Low PA    3.1 (3.1)   1, 10 
Moderate PA   7.6 (3.8)   0, 14 
High PA    5.4 (2.6)   2, 9 
HADS Depression subscale 
Low PA    3.0 (2.2)   0, 7 
Moderate PA   5.6 (5.1)   0, 19 
High PA    4.1 (3.7)   0, 9 
 
*Based on the International Physical Activity Questionnaire; ISI = Insomnia Severity 
Scale; PA = Physical Activity; FSS = Fatigue Severity Scale; HADS = Hospital and 
Anxiety Depression Scale. 
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APPENDIX 2.13 
 
POST-HOC ANALYSIS OF IPAQ CATEGORIES 
 
Participants categorised in the lowest level of activity had the least number of 
physical activity minutes (median = 150.0) and those individuals who met 
criteria for higher levels of participation had the most minutes (median = 
1560).  Participants classified as ‘moderate’ had a median of 585 minutes of 
physical activity.  Post hoc Mann-Whitney tests were used to test for 
differences between the three groups.  A Bonferroni correction was applied 
and so all effects are reported at a 0.017 level of significance.  The analysis 
showed that activity minutes were significantly affected by intensity level.  
Participants who engaged in higher levels of activity reported significantly 
more minutes of activity, compared to those engaged in moderate-intensity 
(U = 111, z = 3.174, p < 0.01, r = .7) and lower levels of activity (U = 28, z = 
3.141, p < 0.01, r = .8).  Similarly, individuals who engaged in moderate 
levels of activity reported significantly more minutes of activity than those 
who engaged in lower levels of activity (U = 87, z = 3.662, p < 0.01, r = .7).  
Effect sizes were large indicating fairly substantive findings.   
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APPENDIX 2.14 
Spearman correlation coefficients for IPAQ activity minutes per week 
and measures of Sleep, Fatigue and Mood (N=28) 
 
Variable   rs   Sig.  p 
_____________________________________________________ 
ISI     .1  NS*  0.568 
FSS    .1  NS  0.519 
HADS Anxiety  .4  Sig**  0.040 
HADS Depression   .2  NS  0.275 
___________________________________________________________ 
*NS = not significant (p > 0.05, two-tailed). 
** Correlation is significant at the 0.05 level (two-tailed). 
IPAQ = International Physical Activity Questionnaire; ISI = Insomnia Severity 
Scale; FSS = Fatigue Severity Scale; HADS = Hospital and Anxiety 
Depression Scale. 
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APPENDIX 2.15 
 
 
Spearman’s correlation coefficients for IPAQ MET-minutes per week 
and measures of Sleep, Fatigue and Mood (N=28) 
 
     
Variable   rs   Sig.  p 
_____________________________________________________________ 
  
ISI     .1  NS*  0.620 
FSS    .1  NS  0.662 
HADS Anxiety  .3  NS  0.082 
HADS Depression   .2  NS  0.362 
_____________________________________________________________ 
 
*NS = not significant (p > 0.05, two-tailed). 
IPAQ = International Physical Activity Questionnaire; ISI = Insomnia Severity 
Scale; FSS = Fatigue Severity Scale; HADS = Hospital and Anxiety 
Depression Scale. 
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APPENDIX 2.16 
 
 
Descriptive Statistics of the IPAQ, ISI, FSS and HADS 
  
 
Variable Mean  SD  Min, Max Median IQR 
___________________________________________________________________ 
 
IPAQ  826.9  723.2  0, 2550 585.0  1018 
 
ISI  11.1  10.5  2, 28  10.5  10 
 
FSS  33.9  10.3  9, 63  34  19 
 
HADS  
Anxiety 5.9  3.7  0, 14  5.0  7 
 
HADS 
Depression 4.6  4.3  0, 19  3.0  6 
 
IPAQ = International Physical Activity Questionnaire; ISI = Insomnia Severity Scale; 
FSS = Fatigue Severity Scale; HADS = Hospital and Anxiety Depression Scale. 
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APPENDIX 2.17 
 
GUIDELINES FOR SUBMISSION TO CANCER NURSING 
 
Manuscript Preparation 
 
Manuscripts must adhere to the following instructions or they will be rejected before 
undergoing peer review.  
 
Abstract: The Abstract is attached as a Word document during the submission 
process. 
Please use the following format for all abstracts; ALL SIX SUBHEADINGHS ARE 
REQUIRED: 
 
Background: 1 to 3 statements describing existing knowledge and significance of 
study  
 
Objective: 1 to 3 statements regarding study aims  
 
Interventions/Methods: 1 to 3 statements describing intervention or data collection 
methods  
 
Results: 1 to 3 statements about sample and findings  
 
Conclusions: 2 to 3 statements about how findings can be interpreted  
 
Implications for Practice: 2 to 3 statements regarding how one or more study 
findings can be translated into clinical care or practice. Identify both dated 
information that needs to be released and information that is confirmed or new.  
 
Word limit: 250 words  
 
Do not cite references in the abstract. Limit the use of abbreviations and acronyms.  
 
Key words: Key words are inserted into a designated box during the submission 
process. Provide up to ten key words, separated by semicolons, that describe the 
contents of the manuscript like those that appear in Cumulative Index to Nursing & 
Allied Health Literature (CINAHL) or The National Library of Medicine's Medical 
Subject Headings (MeSH). The key words are used in indexing your manuscript 
when it is published.  
 
Title page: The title page will be submitted as a separate file when you are 
instructed to attach files to your submission. Compose your title page using your 
word processor, then attach this file when you reach the “attach files” step in the 
submission process. The title page should be formatted according to the example at 
AMA STYLE (10th ed.) STANDARDIZATION under “Author Resources” on our 
website. Include on the title page (a) complete manuscript title; (b) all authors’ full 
names, highest academic degrees, and affiliations; (c) corresponding author's 
name, affiliation(s), address, and e-mail address; and (d) any acknowledgements, 
credits or disclaimers. Include acknowledgement of all sources of funding.  
 
The title page must also include disclosure of funding received for this work from 
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any of the following organizations: National Institutes of Health (NIH); Wellcome 
Trust; Howard Hughes Medical Institute (HHMI); and other(s). 
 
Manuscript: The manuscript will be submitted as a separate file when you are 
instructed to attach files to your submission. Compose your manuscript using your 
word processor, then attach this file when you reach the "attach files" step in the 
submission process. 
 
Please note the following guidelines for preparing your manuscript:  
Prepare the manuscript double spaced in Microsoft Word. Leave a one-inch 
margin on all sides. Do not right justify.  
Type all headings on a separate line.  
Number all manuscript pages consecutively in the upper right-hand corner (text 
and references, followed by illustrations on separate pages).  
All legends for Tables and Figures are to be included with the manuscript; 
include these at the end of manuscript after the list of references. Tables and 
Figures are attached as separate files when you reach "attach files" in the 
submission process. Prepare tables and figures in a format ready for 
reproduction. Further instructions for preparing figures are given below.  
Manuscript length (excluding all references, tables, figures) should be no more 
than 20 pages (standard 8.5 x 11 inch page size).  
Use the American Medical Association Manual of Style, 10th edition, copyright 
2007, for citations and references. See examples for citations and 
references below.  
No identifying information (authors' names) should be included on the 
manuscript.  
Abbreviations: Write out the full term for each abbreviation at its first use unless it 
is a standard unit of measure. 
References: The reference list is not to exceed 50 entries. Authors are responsible 
for the accuracy of the references. Key the references (double-spaced) at the end of 
the manuscript. Cite the references in text in the order of appearance. Cite 
unpublished data—such as papers submitted but not yet accepted for publication 
and personal communications, including e-mail communications—in parentheses in 
the text.  
The citations and reference list is to be styled according to the American Medical 
Association Manual of Style, 10th edition, copyright 2007, AMA.  
 
Figures: Figures will be submitted as a separate file when you are instructed to 
attach files to your submission. Electronic art should be created/scanned and saved 
and submitted as either a TIF (tagged image file format), an EPS (encapsulated 
postscript) file, or a PPT (Power Point) file. Figures submitted as Word documents 
(suffix=.doc) will be rejected. DO NOT USE COLOR, SHADING, SCREENS OR 
FINE LINES. Line art must have a resolution of at least 1200 dpi (dots per inch), 
and scanned images must have a resolution of at least 300 dpi. If fonts are used in 
the artwork, they must be converted to paths or outlines or they must be embedded 
in the files. Please note that artwork generated from office suite programs such 
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ABSTRACT 
Background:  Obesity and a sedentary lifestyle are highly prevalent in 
breast cancer survivors.  A growing number of publications show significant 
associations between low levels of physical activity, obesity and increased 
mortality.  Sleep problems, fatigue, mood disturbance and weight gain are 
common side-effects of a cancer diagnosis and adjuvant treatment. While 
many studies include measures of fatigue and mood, few studies have 
examined the direct relationship of physical activity with level of sleep 
disturbance.   
Aims:  The present study aims to examine the relationship between physical 
activity and sleep, as well as variables of fatigue and mood following a breast 
cancer diagnosis. 
Methods:  A cross-sectional correlational design will be used. Twenty-six 
breast cancer patients will be recruited from hospital sites within NHS 
Greater Glasgow and Clyde and asked to complete questionnaires 
assessing physical activity, sleep quality, fatigue and mood. Actigraphy will 
be used as an objective measure of physical movement in a subsample of 
patients.  
Applications:  Findings will highlight the importance of enquiring about 
physical activity levels following a breast cancer diagnosis and educating 
patients about the health benefits that participation may provide both during 
and after active treatment.   
133 
 
Introduction 
Breast cancer is the most commonly occurring cancer among women in the 
United Kingdom.  More than 40,000 new cases are reported each year, and 
breast cancer accounts for 30% of the cancer burden in women (excluding 
non-melanoma skin cancer).  Surviving cancer usually means enduring 
sequential combinations of treatment modalities (surgery, radiotherapy, 
chemotherapy and hormone therapy), which can result in significant 
reductions in quality of life.1  Common side effects of breast cancer treatment 
include fatigue, which can result in substantial physical, psychosocial and 
socioeconomic consequences.2  During and after adjuvant chemotherapy the 
prevalence of fatigue is high and fluctuating, with a frequency of 60% to 
90%.3  Persistent sleep disturbance is also associated with fatigue and 
depression,4  with estimates of 38% among breast cancer patients5, 
compared to 20% in the general population6. 
 
In the past, cancer patients were advised to rest and avoid physical effort, 
however, it is now well established that excessive rest and lack of physical 
activity can result in severe physical deconditioning and reduced functional 
capacity.  Moreover, recent systematic reviews and meta-analyses report 
clear benefits of physical activity for cardiovascular fitness among breast 
cancer survivors, with modest outcomes for reducing fatigue, improving 
mood and quality of life.7,8  The results are mixed, however, with a recent 
Cochrane review9 examining the effects of exercise on breast cancer 
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patients finding no improvements in quality of life, whereas, an earlier review 
concluding that exercise is effective for improving quality of life.10  
 
Despite these and other well documented benefits of physical activity, a large 
proportion of breast cancer survivors do not perform regular physical 
activity.11 Similarly, many breast cancer patients decrease their physical 
activity level after diagnosis, highlighting the need for intervention.  These 
decreases tend to be associated with the type of adjuvant treatment they 
receive, with the greatest decreases in physical activity observed among 
women who are treated with radiation and chemotherapy (50% decrease), 
compared to women who undergo surgery only (24% decrease).  Other 
reasons for reductions in activity levels include that women may become 
fearful of overexertion and are uncertain of what they can do while receiving 
treatment. This often means that most physical activity ceases, which further 
contributes to the debilitation of the person and compounds the fatigue 
attributable to adjuvant therapy. Furthermore, physical activity tends to be 
largely neglected within cancer care and is not an inherent part of 
rehabilitation programmes.12 This is a stark contrast to cardiac settings 
where exercise is considered an essential component of cardiac 
rehabilitation.   
 
While many studies include measures of fatigue and mood, relatively few 
studies have examined the direct relationship of physical activity levels with 
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sleep quality.  One study that was identified, examined the relationship 
between the level of physical activity and sleep problems in a sample of 
cancer survivors.13  The results suggest that poorer sleep quality was found 
among breast cancer survivors (65.7%) compared to prostate cancer 
survivors (43%).  The results also show higher levels of fatigue in those 
participants who reported no physical activity (M=31), compared to those 
who reported high levels of physical activity (M=42).  
The aim of the current study is to explore the relationship between levels of 
physical activity and sleep, as well as variables of fatigue and mood. A 
secondary aim will be to contribute to the literature on exercise in breast 
cancer patients by including an additional measure of physical activity. The 
“stages of behaviour change” model will be used as a theoretical framework 
to help understand the stages people go through as they attempt to change 
behaviour following a cancer diagnosis.14  The proposed study is an 
extension of a prospective quantitative study (NHS REC Ref no. 
10/S0709/68) being conducted by researchers at the University of Glasgow 
Sleep Centre (UGSC).  Funded by Breast Cancer Campaign, the core study 
aims to identify prognostic factors for the development of persistent insomnia 
post cancer treatment.  It does not however include physical activity as a 
mediating factor, which is important, as we know that exercise can lead to 
improvements in patient well-being and quality of life.  A practical and 
effective focus upon physical activity may be something that would 
significantly improve patients’ ability to cope with the stress of cancer 
diagnosis and treatment and also result in better post-treatment well-being.   
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Aims and Hypotheses 
Primary Aims 
1. To examine the relationship between physical activity levels and 
sleep, as well as variables of fatigue and mood following a breast 
cancer diagnosis. 
2. To contribute to the findings of the core study by including physical 
activity as an additional measure. 
 
Secondary Aims 
1. To evaluate the test-retest reliability of the International Physical 
Activity Questionnaire (IPAQ). 
2. To validate the use of the IPAQ in a subsample of patients by 
comparing self-reported physical activity levels (IPAQ) with objective 
levels of physical movement (actigraphy). 
Hypotheses 
(i) Lower levels of physical activity, as measured by the IPAQ will be 
related to poorer sleep quality, as measured by the Insomnia Severity 
Index (ISI). 
(ii) Lower levels of physical activity will be related to higher levels of 
fatigue, as measured by the Fatigue Severity Scale (FSS). 
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(iii) Lower levels of physical activity will be related to higher levels of 
anxiety and depression, as measured by the Hospital Anxiety and 
Depression Scale (HADS). 
(iv) Time 1 IPAQ scores will correlate with T2 and T3 IPAQ scores. 
(v) Time 1 IPAQ scores will add to the prediction of Time 2 IPAQ and 
actigraphy scores. 
(vi) Episodes of vigorous physical activity will correlate with higher levels 
of activity as measured by actigraphy.  
 
Plan of Investigation 
Participants 
Participants will have a diagnosis of breast cancer and be receiving anti-
cancer treatment (chemotherapy, radiotherapy or hormone-therapy). For 
inclusion in the study, participants will be female and over 18 years old, have 
a current diagnosis of breast cancer and commenced anti-cancer treatment.  
Participants will be excluded if they have an estimated prognosis fewer than 
six months, confusional problems or drug misuse, evidence of another sleep 
disorder or untreated psychiatric disorder. 
 
 
 
138 
 
Recruitment Procedures 
Participants will be recruited from the Beatson West of Scotland Cancer 
Centre (BWoSCC) and NHS GG&C satellite sites.  All newly diagnosed 
breast cancer patients will be given an information leaflet about the study by 
their clinical care team.  Patients will then be approached by a clinical 
research nurse (employed by the core project), who will provide additional 
study information and answer questions.  Leaflets will have an opt-in section 
and telephone number so that those willing to participate can identify 
themselves.  The trainee will obtain informed consent and conduct 
participant interviews at a location most convenient to the patient.  Due to the 
sensitivity around recruitment at the acute end of cancer care, breast care 
nurses will provide support to all participants at each site.  
 
Measures 
Data collection comprises assessments of physical activity, sleep quality and 
psychosocial functioning, obtained at a single time-point six to nine months 
post treatment.  Actigraphy will be used to provide validation data and 
objective levels of physical movement.  Demographic (age, marital status 
and occupation) and clinical information will also be obtained from all 
participants. 
(i) Glasgow Sleep Centre Interview  
A full sleep history will be taken using the Glasgow Sleep Centre Interview.  
The GSCI is a semi-structured measure which gathers qualitative information 
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about sleep quality and sleep behaviour and takes approximately 20 minutes 
to complete. 
(ii) International Physical Activity Questionnaire 
 
The International Physical Activity Questionnaire (IPAQ) short form will be 
used as the primary outcome measure in the study.15  The IPAQ short form 
is a 4-item self-report instrument that measures physical activity over the 
past seven days. The short version of the IPAQ was selected for use in this 
study as it is designed primarily for monitoring purposes, whereas the long 
IPAQ form is a more detailed assessment recommended for use in 
intervention studies. To reduce any additional burden placed on participants, 
the scale will be adapted for use in the cross-sectional part of the study by 
asking participants to indicate the number of hours and minutes for each 
physical activity in a ‘typical day’, rather than the past seven days.  The 7-
day recall version of the IPAQ will be used in a subsample of participants for 
the validation study. The IPAQ short form assesses three specific types of 
activity: (a) walking (b) moderate-intensity activities and (c) vigorous-intensity 
activities and only counts sessions lasting 10 minutes or longer.  This reflects 
current scientific evidence that the physiological changes associated with 
health benefits from physical activity require a minimum duration.  An 
additional question measures time spent sitting which can be used as an 
indication of sedentary time.  The items on the short IPAQ form are 
structured to provide separate scores on walking, moderate-intensity and 
vigorous-intensity activity.  Computation of the total score requires 
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summation of the duration (in minutes) and/or frequency (days) of walking, 
moderate-intensity and vigorous-intensity activities.  Algorithms are used to 
classify three levels of physical activity into low, moderate or high categories.  
The IPAQ instruments have been tested extensively in countries around the 
world and have acceptable measurement properties that are comparable to 
other established self-report questionnaires.   
 
(iii) Actigraphy and Sleep Diary 
Actigraphs will be used to provide an objective measure of physical 
movement. The actigraph is a nonintrusive device that records movement for 
1-minute epochs through a wrist-watch microprocessor link.16  Activity/rest 
variables include mesor to represent overall mean activity levels, amplitude 
to represent the ability to meet both higher and lower activity/rest 
requirements, and night time awakenings as indicators of restlessness and 
interruptions during sleep.  Resourcing 82 wrist actigraphs at any one time is 
outwith the scope of the current study, however, providing 10 actigraphs is 
feasible.  A subsample of approximately 10 participants will be invited to 
wear a wrist actigraph on their non-dominant wrist for a period of seven days.  
Participants will also be asked to complete a sleep diary over the same 7-day 
period as a measure of subjective sleep pattern. 
(iv) Insomnia Severity Index  
The Insomnia Severity Index (ISI)17 will be used to examine the proportion of 
participants that reach threshold for a significant sleep disturbance.  The ISI 
141 
 
is a brief self-report instrument and is considered to be a core assessment 
tool for use in insomnia research studies.  
(v) Fatigue Severity Scale 
The Fatigue Severity Scale (FSS)18 will be used to evaluate the impact of 
fatigue.  The FSS was originally developed as a tool to assess fatigue in 
patients with multiple sclerosis. The questionnaire has nine statements 
inquiring about the patient’s sleep habits over the preceding week. 
Participants will be asked to rate their level of agreement (toward seven) or 
disagreement (toward zero) with the nine statements.  A score of 36 and 
above (out of a maximum of 63) indicates the presence of significant fatigue.  
(vi) Hospital Anxiety and Depression Scale 
Mood will be measured using the Hospital Anxiety and Depression Scale 
(HADS).19 The HADS is a brief 14-item self-report measure, which is widely 
used to assess anxiety and depression in patients with medical conditions.  
The scale is quick and easy to administer and consists of two subscales of 
seven items designed to measure levels of anxiety and depression, each of 
which has cut-off points to identify caseness.     
The questionnaires have satisfactory internal consistency (Cronbach’s α of ≥ 
.70) and in total, completion time for these measures will be around 20 
minutes. 
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Design 
A cross-sectional correlational design will be used to examine the 
relationship between physical activity, sleep, fatigue and mood at a single 
time point, six to nine months post-treatment.  To test the reliability of the 
IPAQ a subsample of participants will be asked to complete the IPAQ at 
Time 1 (baseline) and again at Time 2 (1-week later) and Time 3 (3-weeks 
later).  To assess concurrent validity of the IPAQ, objective data from 
actigraphy will be compared with IPAQ scores at Time 2. 
 
Research Procedures 
Participant screening interviews and assessments will be carried out by the 
trainee.  Due to the anticipated poor health of this group all participants will 
have the opportunity to complete assessments online from their own homes.  
This will be done using a secure online data collection system which will be 
set up and maintained by the UGSC.  Face to face assessments will also be 
available should participants prefer this.   
 
Justification of Sample Size 
There is a lack of research directly measuring the relationship between 
physical activity and sleep disturbance in women with breast cancer.  Studies 
of related constructs were therefore used to estimate sample size needed to 
obtain power of 0.8 at an alpha of 0.05, prior to commencing this study.  
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Humpel and Iverson20 compared 32 breast cancer patients with 59 prostate 
cancer patients and found statistically significant differences on measures of 
physical activity and sleep quality.  A greater proportion of breast cancer 
(36.7%) than prostate cancer patients (15.5%) reported poor sleep latency 
and sleep disturbance (48.4% vs. 17.2%).  Additionally, the mean minutes of 
moderate physical activity were lower among those reporting poor sleep 
quality. 
 
Using data from this study, effect sizes were calculated by dividing the F-
ratio by the square root of the residual degrees of freedom.21  The effect size 
of the difference in mean scores on measures of physical activity and sleep 
quality were medium (r = 0.30).  For the present study, GPower analysis 
estimates that 82 participants will be required to detect an effect of this 
magnitude (r = 0.30, with 80% power and α = p>0.05, two-tailed).  For a 
large effect size (r = 0.50) the study will require 26 participants.  Given that it 
is intended to use individuals of the same gender and similar cancer site 
(women with breast cancer), it is expected that a sample size of 26 will be 
sufficient to detect associations if they exist.   
 
Settings and Equipment 
The study will take place at the BWoSCC, the UGSC and NHS GG&C 
satellite sites.  An online data collection system will be used as well as the 
measures outlined above. 
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Data Analysis 
If the assumptions for parametric tests are met, primary analyses will include 
Pearson’s correlations to assess the relationship between physical activity 
with variables of sleep, fatigue and mood. Partial correlations will also be 
carried out between physical activity and sleep while controlling for the 
effects of fatigue and mood.  Secondary analyses will include test-retest 
correlations over a 3-week interval to examine the reliability of T1 and T2 
measures.  If participant numbers allow, multiple regression analyses will be 
conducted to examine predictors of physical activity (age, type of cancer 
treatment, sleep quality, fatigue and mood).  Correlations between IPAQ 
scores and actigraphy data will be conducted to assess concurrent validity. 
 
Health and Safety Issues 
Researcher Safety Issues 
The project will be based within a safe environment with Dr Leanne Fleming 
(University Co-Supervisor) and Professor Colin Espie (University Supervisor) 
providing supervisory support.    
Participant Safety Issues 
Participant screening interviews and assessments will be conducted under 
the supervision of the university supervisors.  Should participants express 
any distress during interviews, the researcher will ensure that a member of 
the clinical team is available for consultation.  
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Ethical Issues 
Informed consent will be obtained from all participants by the trainee after 
ensuring full understanding of the study.  Should any participant express 
distress during interviews, the researcher will ensure that a member of the 
clinical team is available for consultation.  Ethical approval and local 
research and development permissions will be obtained from NHS GG&C.   
 
Financial Issues 
Equipment costs, travel etc. 
The online data collection system and supply of test materials will be 
undertaken by the UGSC project team at no additional cost.  
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Timetable 
Time in 
months 
Principal tasks 
0-3 Submit MRP Outline (13.12.10); submit MRP Draft Proposal 
(31.01.11) 
4-6 Submit MRP Proposal (16.05.11) 
7-10 Submit Systematic Review Outline (26.08.11); apply for ethics 
and R&D approval; order materials 
10-14 Commence participant recruitment; prepare data sheets and files 
15-19 Data entry; preliminary analysis  
18-19 Complete data analysis; final write-up; prepare papers for 
publication 
 
Practical Applications 
It is anticipated that the study will provide preliminary evidence of a 
relationship between low levels of physical activity with poor sleep quality, 
greater fatigue and mood disturbance after a breast cancer diagnosis.  This 
is important, as being physically active post-diagnosis could help improve 
quality of life and prevent the development of chronic insomnia and other 
cancer-related symptoms, such as depression and fatigue in an already 
vulnerable population.  The findings from this pilot study could also be used 
to determine the feasibility of conducting a large-scale national study. 
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